@NP	The Cotransplantation	1
@NP	Olfactory Ensheathing Cells	26
@NP	Bone Marrow Mesenchymal Stem Cells	59
@NP	Antiapoptotic Effects in Adult Rats	101
@NP	Antiapoptotic Effects	101
@NP	Adult Rats	126
@NP	Spinal Cord Injury ShifengWu ,1 Guanqun Cui ,2 Hua Shao ,3 Zhongjun Du ,3	143
@NP	Jack C.	214
@NP	Ng ,4	222
@NP	Cheng Peng4 The mechanisms	231
@NP	the repairing effects	266
@NP	the cotransplantation	291
@NP	olfactory ensheathing cells -LRB- OECs -RRB-	316
@NP	olfactory ensheathing cells	316
@NP	OECs	345
@NP	bone marrow mesenchymal stromal cells -LRB- BMSCs -RRB-	356
@NP	bone marrow mesenchymal stromal cells	356
@NP	bone marrow	356
@NP	BMSCs	395
@NP	understood.Therefore	422
@NP	we	444
@NP	the effects of the cotransplantation of OECs with BMSCs on antiapoptotic effects	460
@NP	the effects	460
@NP	the cotransplantation of OECs with BMSCs on antiapoptotic effects	475
@NP	the cotransplantation	475
@NP	OECs with BMSCs on antiapoptotic effects	500
@NP	OECs	500
@NP	BMSCs on antiapoptotic effects	510
@NP	BMSCs	510
@NP	antiapoptotic effects	519
@NP	adult rats for which the models of SCI are induced	544
@NP	adult rats	544
@NP	the models of SCI	565
@NP	the models	565
@NP	SCI	579
@NP	We	596
@NP	the changes	608
@NP	body weight	623
@NP	histopathological changes	636
@NP	apoptosis	663
@NP	the expressions of apoptosis-related proteins	678
@NP	the expressions	678
@NP	apoptosis-related proteins	697
@NP	14 days and 28 days	730
@NP	14 days	730
@NP	28 days	742
@NP	transplantation	756
@NP	We	773
@NP	animal	790
@NP	locomotion using BBB test	797
@NP	locomotion	797
@NP	BBB test	814
@NP	We	824
@NP	treatment with OECs and BMSCs	838
@NP	treatment	838
@NP	OECs and BMSCs	853
@NP	a remissive effect on behavioral outcome	872
@NP	a remissive effect	872
@NP	behavioral outcome	894
@NP	histopathological changes	917
@NP	SCI	951
@NP	we	969
@NP	the significant antiapoptotic effect	981
@NP	cotransplant treated group	1021
@NP	addition	1052
@NP	cotransplantation of OECs with BMSCs	1062
@NP	cotransplantation	1062
@NP	OECs with BMSCs	1083
@NP	OECs	1083
@NP	BMSCs	1093
@NP	more significant repairing effect than that of OECs or BMSCs alone	1117
@NP	more significant	1117
@NP	effect	1144
@NP	that of OECs or BMSCs	1156
@NP	that	1156
@NP	OECs or BMSCs	1164
@NP	the recovery of hind limb	1198
@NP	the recovery	1198
@NP	hind limb	1214
@NP	antiapoptotic effect of OECs and BMSCs	1244
@NP	antiapoptotic effect	1244
@NP	OECs and BMSCs	1268
@NP	the apoptotic pathways	1306
@NP	our data	1339
@NP	the cotransplantation of OECs with BMSCs	1358
@NP	the cotransplantation	1358
@NP	OECs with BMSCs	1383
@NP	OECs	1383
@NP	BMSCs	1393
@NP	promise for a potential cure after SCI	1405
@NP	promise	1405
@NP	a potential cure after SCI	1417
@NP	a potential cure	1417
@NP	SCI	1440
@NP	the ability to incorporate into the spinal cord	1452
@NP	the spinal cord	1484
@NP	Introduction Spinal cord injury -LRB- SCI -RRB-	1505
@NP	Introduction Spinal cord injury	1505
@NP	Introduction	1505
@NP	Spinal cord injury	1518
@NP	SCI	1538
@NP	a destructive neurologic injury	1546
@NP	functional deficits due to the loss of spinal cord neurons and axons	1591
@NP	functional deficits	1591
@NP	the loss of spinal cord neurons and axons	1618
@NP	the loss	1618
@NP	spinal cord neurons and axons	1630
@NP	Extensive attempts	1661
@NP	repair and recovery cells	1706
@NP	the injury for potential treatments of SCI	1737
@NP	the injury	1737
@NP	potential treatments of SCI	1752
@NP	potential treatments	1752
@NP	SCI	1776
@NP	the use of stem cells as transplant tissue	1792
@NP	the use	1792
@NP	stem cells as transplant tissue	1803
@NP	stem cells	1803
@NP	transplant tissue	1817
@NP	particular promise	1841
@NP	they	1866
@NP	endogenous destroyed cells through facilitating cell regeneration	1883
@NP	endogenous	1883
@NP	cells	1904
@NP	cell regeneration	1931
@NP	neurons -LSB- 1 -RSB-	1972
@NP	neurons	1972
@NP	1 -RSB-	1981
@NP	Cellbased therapies	1985
@NP	beneficial effects	2023
@NP	different types of cells in preclinical models	2048
@NP	different types	2048
@NP	cells in preclinical models	2067
@NP	cells	2067
@NP	preclinical models	2076
@NP	-LSB- 2 , 3 -RSB-	2095
@NP	Olfactory ensheathing cells -LRB- OECs -RRB-	2103
@NP	Olfactory ensheathing cells	2103
@NP	OECs	2132
@NP	bone marrow mesenchymal stromal stem cells -LRB- BMSCs -RRB-	2142
@NP	bone marrow mesenchymal stromal stem cells	2142
@NP	BMSCs	2186
@NP	two	2197
@NP	the most	2204
@NP	cells for SCI repair	2221
@NP	cells	2221
@NP	SCI repair	2231
@NP	experimental models	2245
@NP	good perspectives	2276
@NP	clinical applications of cell therapy	2298
@NP	clinical applications	2298
@NP	cell therapy	2323
@NP	OECs	2337
@NP	unique glial cells	2346
@NP	the olfactory systems	2374
@NP	olfactory neurogenesis	2409
@NP	the retargeting across the peripheral nervous system/the	2436
@NP	the retargeting	2436
@NP	the peripheral nervous system/the	2459
@NP	central nervous system boundary in the olfactory system	2493
@NP	central nervous system boundary	2493
@NP	the olfactory system	2528
@NP	These cells	2550
@NP	tissue sparing and neuroprotection	2584
@NP	outgrowth	2628
@NP	both intact and lesioned axons	2641
@NP	angiogenesis	2682
@NP	remyelinate axons after a range of demyelinating insults -LSB- 4 -RSB-	2700
@NP	remyelinate axons	2700
@NP	a range of demyelinating insults -LSB- 4 -RSB-	2724
@NP	a range	2724
@NP	demyelinating insults -LSB- 4 -RSB-	2735
@NP	demyelinating insults	2735
@NP	4 -RSB-	2758
@NP	Recent studies	2762
@NP	OEC	2793
@NP	the differentiation of stem cells	2809
@NP	the differentiation	2809
@NP	stem cells	2832
@NP	the olfactory system	2848
@NP	the olfactory neurons	2876
@NP	-LSB- 5 , 6 -RSB-	2898
@NP	Acute transplantation of OECs into partial or complete spinal cord lesions	2906
@NP	Acute transplantation	2906
@NP	OECs into partial or complete spinal cord lesions	2931
@NP	OECs	2931
@NP	partial or complete spinal cord lesions	2941
@NP	the volume of injured tissue	3006
@NP	the volume	3006
@NP	injured tissue	3020
@NP	axonal regeneration	3044
@NP	some functions -LSB- 7 -RSB-	3077
@NP	some functions	3077
@NP	7 -RSB-	3093
@NP	The proposed mechanisms of action of grafted OECs	3097
@NP	The proposed mechanisms	3097
@NP	action of grafted OECs	3124
@NP	action	3124
@NP	grafted OECs	3134
@NP	their interaction	3155
@NP	astrocytes	3178
@NP	8 -RSB-	3190
@NP	modulation	3194
@NP	the early neuroinflammatory response	3208
@NP	9 -RSB- , remyelination and enhancement	3246
@NP	axonal regeneration -LSB- 10 -RSB- , and promotion of angiogenesis	3283
@NP	axonal regeneration	3283
@NP	10 -RSB- , and promotion of angiogenesis	3304
@NP	10 -RSB-	3304
@NP	promotion of angiogenesis	3313
@NP	promotion	3313
@NP	angiogenesis	3326
@NP	progenitor OECs	3351
@NP	one of the most promising cell sources	3389
@NP	one	3389
@NP	the most promising cell sources	3396
@NP	SCI therapy	3432
@NP	BMSCs	3445
@NP	functional recovery	3489
@NP	-LSB- 11 , 12 -RSB-	3509
@NP	intrathecal injection or intravenous perfusion	3522
@NP	intrathecal injection	3522
@NP	intravenous perfusion	3547
@NP	The mechanisms underlying the beneficial effects of BMSCs transplants	3570
@NP	The mechanisms	3570
@NP	the beneficial effects of BMSCs transplants	3596
@NP	the beneficial effects	3596
@NP	BMSCs transplants	3622
@NP	neuroprotection	3652
@NP	the expression	3693
@NP	neuroprotective molecules in the injured tissues -LSB- 12 -RSB-	3711
@NP	neuroprotective molecules	3711
@NP	the injured tissues -LSB- 12 -RSB-	3740
@NP	the injured tissues	3740
@NP	12 -RSB-	3761
@NP	contribution	3766
@NP	a permissive environment	3782
@NP	axonal regeneration and neural tissue reconstruction -LSB- 13 -RSB-	3811
@NP	axonal regeneration and neural tissue reconstruction	3811
@NP	13 -RSB-	3865
@NP	acceleration of the tissue repair process -LSB- 9 -RSB-	3870
@NP	acceleration	3870
@NP	the tissue repair process -LSB- 9 -RSB-	3886
@NP	the tissue repair process	3886
@NP	9 -RSB-	3913
@NP	modulation of the neuroinflammatory response	3921
@NP	modulation	3921
@NP	the neuroinflammatory response	3935
@NP	recent years	3970
@NP	much attention	3984
@NP	secondary cord injury	4016
@NP	this	4044
@NP	therapeutic intervention	4079
@NP	Apoptosis and inflammatory responses and some other neurological toxicity events	4105
@NP	Apoptosis and inflammatory responses	4105
@NP	some other neurological toxicity events	4146
@NP	the secondary injury	4198
@NP	primary insult in the spinal cord -LSB- 1 -RSB-	4225
@NP	primary insult	4225
@NP	the spinal cord -LSB- 1 -RSB-	4243
@NP	the spinal cord	4243
@NP	1 -RSB-	4260
@NP	Apoptosis	4263
@NP	both a receptor-dependent extrinsic pathway and mitochondria	4282
@NP	a receptor-dependent extrinsic pathway	4287
@NP	mitochondria	4330
@NP	spinal cord injuries	4357
@NP	spinal cord injuries -LSB- 14 -RSB-	4402
@NP	spinal cord injuries	4402
@NP	14 -RSB-	4424
@NP	Several studies	4429
@NP	the apoptotic role of caspases	4461
@NP	the apoptotic role	4461
@NP	caspases	4483
@NP	the injured spinal cord -LSB- 15	4495
@NP	the injured spinal cord	4495
@NP	15	4520
@NP	17 -RSB-	4523
@NP	Activation of Caspase-3 and Caspase-8 and apoptosis	4528
@NP	Activation	4528
@NP	Caspase-3 and Caspase-8 and apoptosis	4542
@NP	a temporally similar fashion after SCI -LSB- 18 -RSB-	4589
@NP	a temporally similar fashion	4589
@NP	SCI -LSB- 18 -RSB-	4624
@NP	SCI -LSB-	4624
@NP	Many other genes	4634
@NP	apoptosis , such as the antiapoptosis gene Bcl-2 and apoptosisinducer Bax	4667
@NP	apoptosis	4667
@NP	the antiapoptosis gene Bcl-2 and apoptosisinducer Bax	4686
@NP	a study using Bcl-2 overexpressed transgenic mice	4751
@NP	a study	4751
@NP	Bcl-2 overexpressed transgenic mice	4765
@NP	Bcl-2	4765
@NP	transgenic mice	4785
@NP	overexpression of Bcl - 2	4819
@NP	overexpression	4819
@NP	Bcl - 2	4837
@NP	Bcl	4837
@NP	2	4842
@NP	neuronal apoptosis	4854
@NP	spinal cord injury	4879
@NP	recovery of neurological function	4911
@NP	recovery	4911
@NP	neurological function	4923
@NP	19 -RSB-	4946
@NP	contrast	4954
@NP	Bax , a cytosolic protein in normal living cells ,	4964
@NP	Bax	4964
@NP	a cytosolic protein in normal living cells	4969
@NP	a cytosolic protein	4969
@NP	normal living cells	4992
@NP	apoptosis	5024
@NP	tomitochondria	5059
@NP	an early stage of the apoptotic process	5077
@NP	an early stage	5077
@NP	the apoptotic process	5095
@NP	Kotipatruni et al. -LSB- 20 -RSB-	5118
@NP	Kotipatruni et al. -LSB-	5118
@NP	upregulation of Bax and downregulation of Bcl-2	5149
@NP	upregulation	5149
@NP	Bax and downregulation	5165
@NP	Bcl-2	5191
@NP	rat spinal cords	5200
@NP	SCI.These	5223
@NP	the involvement of a mitochondrial-mediated apoptotic pathway	5251
@NP	the involvement	5251
@NP	a mitochondrial-mediated apoptotic pathway	5270
@NP	SCI	5319
@NP	the natural capacity of the central nervous system to recover from injury	5330
@NP	the natural capacity	5330
@NP	the central nervous system	5354
@NP	injury	5397
@NP	current SCI research	5416
@NP	the use of regenerative potential of OECs or BMSCs	5448
@NP	the use	5448
@NP	regenerative potential of OECs or BMSCs	5459
@NP	regenerative potential	5459
@NP	OECs or BMSCs	5485
@NP	the damaged neurons and oligodendrocytes	5510
@NP	neuronal plasticity	5563
@NP	These studies	5584
@NP	the reduction of neural degeneration and certain functional recovery	5605
@NP	the reduction	5605
@NP	neural degeneration and certain functional recovery	5622
@NP	neural degeneration	5622
@NP	certain functional recovery	5646
@NP	transplantation of either OECs or BMSCs	5677
@NP	transplantation	5677
@NP	either OECs or BMSCs	5696
@NP	A precious study	5718
@NP	the antiapoptotic effects of transplantation of BMSCs	5742
@NP	the antiapoptotic effects	5742
@NP	transplantation of BMSCs	5771
@NP	transplantation	5771
@NP	BMSCs	5790
@NP	spinal cord injury -LSB- 21 -RSB-	5802
@NP	spinal cord injury	5802
@NP	21 -RSB-	5822
@NP	OECs and BMSCs	5837
@NP	damaged organs or tissues	5885
@NP	they	5918
@NP	myocardiocytes and neurons	5942
@NP	cell lineages	5969
@NP	22 -RSB-	5984
@NP	we	6000
@NP	cotransplantation of OECs with BMSCs	6021
@NP	cotransplantation	6021
@NP	OECs with BMSCs	6042
@NP	OECs	6042
@NP	BMSCs	6052
@NP	stronger effects	6067
@NP	neural degeneration induced by SCI	6087
@NP	neural degeneration	6087
@NP	SCI	6118
@NP	We	6123
@NP	the improved neurological functions by cotransplantation of OECs with BMSCs	6152
@NP	the improved neurological functions	6152
@NP	cotransplantation of OECs with BMSCs	6191
@NP	cotransplantation	6191
@NP	OECs with BMSCs	6212
@NP	OECs	6212
@NP	BMSCs	6222
@NP	throughthe regulationofBax,Bcl-2 , Caspase-9 , andCaspase-3	6244
@NP	throughthe regulationofBax,Bcl-2	6244
@NP	Caspase-9 , andCaspase-3	6277
@NP	Caspase-9	6277
@NP	andCaspase-3	6287
@NP	the hypothesis	6309
@NP	we	6325
@NP	OECs and BMSCs	6341
@NP	cotransplantation of OECs	6360
@NP	cotransplantation	6360
@NP	OECs	6381
@NP	BMSCs in rats with SCI	6391
@NP	BMSCs	6391
@NP	rats with SCI	6400
@NP	rats	6400
@NP	SCI	6410
@NP	behavioral activities and histopathological changes	6428
@NP	behavioral activities	6428
@NP	histopathological changes	6454
@NP	the expression	6493
@NP	the protein involved in mitochondria-associated apoptotic pathway	6511
@NP	the protein	6511
@NP	mitochondria-associated apoptotic pathway	6535
@NP	Materials and Methods 2.1 .	6582
@NP	Materials and Methods 2.1	6582
@NP	Materials	6582
@NP	Methods 2.1	6596
@NP	Experimental Animals and Experimental Design .	6609
@NP	Experimental Animals and Experimental Design	6609
@NP	Experimental Animals	6609
@NP	Experimental Design	6634
@NP	Adult female Wistar rats weighting 250	6655
@NP	Adult female Wistar rats	6655
@NP	weighting 250	6680
@NP	300 g	6694
@NP	the Department of Experimental Animals	6720
@NP	the Department	6720
@NP	Experimental Animals	6738
@NP	Shandong University	6760
@NP	China	6781
@NP	the number for certificate of animals	6788
@NP	the number	6788
@NP	certificate of animals	6803
@NP	certificate	6803
@NP	animals	6818
@NP	SCXK -LRB- Lu -RRB- 2013-0009	6829
@NP	SCXK -LRB- Lu -RRB-	6829
@NP	SCXK	6829
@NP	Lu	6835
@NP	2013-0009	6839
@NP	standard housing conditions	6872
@NP	temperature	6901
@NP	18 -- 24 ∘ C ; relative humidity : 45 % ; light and dark cycle : 12 h : 12 h	6914
@NP	18 -- 24 ∘ C	6914
@NP	18	6914
@NP	24 ∘ C	6917
@NP	relative humidity : 45 %	6923
@NP	relative humidity	6923
@NP	45 %	6942
@NP	light and dark cycle	6947
@NP	light	6947
@NP	dark cycle	6957
@NP	12 h : 12 h	6969
@NP	12 h	6969
@NP	12 h	6976
@NP	Food and water	6983
@NP	Food	6983
@NP	water	6992
@NP	ad libitum	7012
@NP	We	7717
@NP	12 animals	7737
@NP	each group	7751
@NP	two groups	7767
@NP	14-day posttransplantation group and 28-day posttransplantation group	7779
@NP	14-day posttransplantation group	7779
@NP	28-day posttransplantation group	7816
@NP	14 and 28 days after transplantation	7854
@NP	14 and 28 days	7854
@NP	transplantation	7875
@NP	the animals -LRB- = 6 -RRB- from each group	7892
@NP	the animals -LRB- = 6 -RRB-	7892
@NP	the animals	7892
@NP	= 6	7908
@NP	each group	7918
@NP	different parameters	7949
@NP	Figure 1	7982
@NP	2.2	7992
@NP	Spinal Cord Injury Model .	7997
@NP	Spinal Cord	7997
@NP	Injury Model	8009
@NP	A standard spinal cord contusion	8023
@NP	the New York University -LRB- NYU -RRB- weight drop device	8074
@NP	New York University -LRB- NYU -RRB-	8078
@NP	New York University	8078
@NP	NYU	8099
@NP	detailed previously -LSB- 16 -RSB-	8126
@NP	16	8147
@NP	the adult female rats	8161
@NP	an operating table covered with a warming blanket	8221
@NP	an operating table	8221
@NP	a warming blanket	8253
@NP	the midthoracic region	8286
@NP	Betadine	8327
@NP	an incision	8337
@NP	the midthoracic region	8363
@NP	Laminectomy on each rat	8387
@NP	Laminectomy	8387
@NP	each rat	8402
@NP	the T9 -- T11 under chloral hydrate anesthesia	8428
@NP	the T9	8428
@NP	T11 under chloral hydrate anesthesia	8435
@NP	T11	8435
@NP	chloral hydrate anesthesia	8445
@NP	The impact rod of the impactor of 10 g	8473
@NP	The impact rod	8473
@NP	the impactor of 10 g	8491
@NP	the impactor	8491
@NP	10 g	8507
@NP	T10	8531
@NP	a height of 50mmto induce a consistent partial SCI	8552
@NP	a height	8552
@NP	50mmto induce a consistent partial SCI	8564
@NP	50mmto	8564
@NP	a consistent partial SCI	8578
@NP	Analgesia	8604
@NP	buprenorphine -LRB- 0.1 mg/kg -RRB- for 2 days	8633
@NP	buprenorphine -LRB- 0.1 mg/kg -RRB-	8633
@NP	buprenorphine	8633
@NP	0.1 mg/kg	8648
@NP	2 days	8662
@NP	surgery	8675
@NP	Gentamicin -LRB- 0.8 mg/100 g , ip -RRB-	8684
@NP	Gentamicin	8684
@NP	0.8 mg/100 g	8696
@NP	ip	8709
@NP	Ringer 's solution to avoid dehydration -LRB- 2mL , ip , after surgery -RRB-	8717
@NP	Ringer 's solution to avoid dehydration	8717
@NP	Ringer 's	8717
@NP	dehydration	8744
@NP	2mL , ip	8757
@NP	2mL	8757
@NP	ip	8762
@NP	surgery	8772
@NP	urinary tract infection for 3 -- 7 days	8811
@NP	urinary tract infection for 3	8811
@NP	urinary tract infection	8811
@NP	3	8839
@NP	7 days	8841
@NP	Passive mobilization of the hind legs for 15 minutes	8849
@NP	Passive mobilization	8849
@NP	the hind legs for 15 minutes	8873
@NP	the hind legs	8873
@NP	15 minutes	8891
@NP	every day for a week	8917
@NP	every day	8917
@NP	a week	8931
@NP	surgery	8944
@NP	Postoperative care	8953
@NP	manual bladder expression	8981
@NP	2 times	9007
@NP	a day	9015
@NP	reflex bladder emptying	9027
@NP	reflex bladder	9027
@NP	2.3	9068
@NP	Culture and Identification of Stem Cells .	9073
@NP	Culture and Identification	9073
@NP	Stem Cells	9103
@NP	OECs	9115
@NP	olfactory bulbs of healthy female adult Sprague Dawley rats -LRB- = 6 -RRB-	9125
@NP	olfactory bulbs	9125
@NP	healthy female adult Sprague Dawley rats -LRB- = 6 -RRB-	9144
@NP	healthy female adult Sprague Dawley rats	9144
@NP	= 6	9189
@NP	weighting 220	9194
@NP	300 g	9208
@NP	slight modifications	9256
@NP	-LSB- 23 , 24 -RSB-	9277
@NP	brief	9290
@NP	the Sprague Dawley ratswere	9297
@NP	the Sprague Dawley	9297
@NP	3 % pentobarbital sodiumanesthetic overdose	9339
@NP	0.5 % iodophor solution	9401
@NP	5 minutes	9434
@NP	rats	9445
@NP	the super-clean bench	9468
@NP	The cranial cavity	9491
@NP	the cranial sagittal suture from the foramen magnum	9524
@NP	the cranial sagittal suture	9524
@NP	the foramen magnum	9557
@NP	Olfactory bulbs	9577
@NP	2 times	9618
@NP	PBS	9631
@NP	small pieces	9646
@NP	sterile ophthalmic scissors	9664
@NP	4 ∘ C DMEM -LRB- with penicillin/streptomycin , 100 / mL -RRB-	9717
@NP	4 ∘ C DMEM	9717
@NP	penicillin/streptomycin , 100 / mL	9732
@NP	penicillin/streptomycin	9732
@NP	100 / mL	9757
@NP	100	9757
@NP	mL	9764
@NP	GIBCO	9769
@NP	USA	9776
@NP	centrifuge	9798
@NP	800 r.p.m	9809
@NP	Thermo Fisher	9820
@NP	USA	9835
@NP	the tissue pieceswere digestedwith 0.125 % pancreatin	9841
@NP	EDTA	9894
@NP	37 ∘ C for 30 minutes	9902
@NP	37 ∘ C	9902
@NP	30 minutes	9911
@NP	The cell suspension with the cells in 104/mL	9923
@NP	The cell suspension	9923
@NP	the cells in 104/mL	9948
@NP	the cells	9948
@NP	104/mL	9961
@NP	CO2 incubator -LRB- Thermo Fisher Labserv CO-150 , USA -RRB-	9998
@NP	CO2 incubator	9998
@NP	Thermo Fisher Labserv CO-150	10013
@NP	USA	10043
@NP	DMEM	10072
@NP	OECswere identifiedby immunohistochemistrywithp75 antibody	10103
@NP	Cells at 60 % confluency	10163
@NP	Cells	10163
@NP	60 % confluency	10172
@NP	3 times	10199
@NP	PBS	10212
@NP	incubation of 4 % paraformaldehyde for 20 minutes at room temperature	10228
@NP	incubation	10228
@NP	4 % paraformaldehyde for 20 minutes at room temperature	10242
@NP	4 % paraformaldehyde	10242
@NP	20 minutes at room temperature	10266
@NP	20 minutes	10266
@NP	room temperature	10280
@NP	5 % BSA for 30 minutes	10323
@NP	5 % BSA	10323
@NP	30 minutes	10334
@NP	the cells	10346
@NP	p75 antibody -LRB- 1 : 100 -RRB- -LRB- Sigma , USA -RRB-	10376
@NP	p75 antibody -LRB- 1 : 100 -RRB-	10376
@NP	p75 antibody	10376
@NP	1 : 100	10390
@NP	1	10390
@NP	100	10394
@NP	Sigma	10400
@NP	USA	10407
@NP	4 ∘ C overnight	10415
@NP	4 ∘	10415
@NP	C overnight	10417
@NP	The cells on slides	10430
@NP	The cells	10430
@NP	slides	10443
@NP	microscope	10468
@NP	fluorescencemicroscope -LRB- OLYMPUS , Japan -RRB-	10496
@NP	fluorescencemicroscope	10496
@NP	OLYMPUS	10520
@NP	Japan	10529
@NP	incubation	10542
@NP	antibody -LRB- 1 : 200 -RRB- -LRB- Sigma , USA -RRB- for 40 minutes at 37 ∘	10571
@NP	antibody -LRB- 1 : 200 -RRB-	10571
@NP	antibody	10571
@NP	1 : 200	10581
@NP	1	10581
@NP	200	10585
@NP	Sigma	10591
@NP	USA	10598
@NP	40 minutes at 37 ∘	10607
@NP	40 minutes	10607
@NP	37 ∘	10621
@NP	BMSCs	10627
@NP	the repeated adherent culture method as described by Qian et al. -LSB- 25 -RSB-	10666
@NP	the repeated adherent culture method	10666
@NP	Qian et al. -LSB- 25 -RSB-	10719
@NP	Qian et al. -LSB-	10719
@NP	Bone marrow was isolated in sterile conditions from 8	10737
@NP	Bone marrow	10737
@NP	sterile conditions	10765
@NP	8	10789
@NP	week-old female healthy Sprague Dawley rats -LRB- = 6 -RRB- weighting 250	10792
@NP	week-old female healthy Sprague Dawley rats	10792
@NP	= 6	10840
@NP	weighting 250	10845
@NP	300 g.	10859
@NP	anesthetic overdose	10901
@NP	rats	10922
@NP	tibia and femur	10949
@NP	antiseptic conditions	10972
@NP	medullar cavitywas	10994
@NP	DMEM	11026
@NP	single cell suspension	11038
@NP	CO2 incubator -LRB- Thermo Fisher Labserv CO-150 , USA -RRB-	11100
@NP	CO2 incubator	11100
@NP	Thermo Fisher Labserv CO-150	11115
@NP	USA	11145
@NP	The cells	11151
@NP	inverted microscope -LRB- OLYMPUS , Japan -RRB-	11187
@NP	inverted microscope	11187
@NP	OLYMPUS	11208
@NP	Japan	11217
@NP	Brdu -LRB- 10 / L -RRB- -LRB- Guangzhou RIBOBIO Co. , Ltd , China -RRB-	11225
@NP	Brdu -LRB- 10 / L -RRB-	11225
@NP	Brdu	11225
@NP	10	11231
@NP	L	11238
@NP	Guangzhou RIBOBIO Co.	11242
@NP	Ltd	11265
@NP	China	11270
@NP	the culture flasks	11292
@NP	incubation for 48	11317
@NP	incubation	11317
@NP	48	11332
@NP	72 h and the cells	11336
@NP	72 h	11336
@NP	the cells	11345
@NP	4 % paraformaldehyde for about 20 minutes	11371
@NP	4 % paraformaldehyde	11371
@NP	about 20 minutes	11395
@NP	The cell slides	11413
@NP	1 % Triton X-100 , digested with 2 % HCl and the pepsin for 10 minutes	11453
@NP	1 % Triton X-100	11453
@NP	2 % HCl and the pepsin for 10 minutes	11484
@NP	2 % HCl	11484
@NP	the pepsin for 10 minutes	11495
@NP	the pepsin	11495
@NP	10 minutes	11510
@NP	5 % BSA -LRB- GIBCO , USA -RRB-	11539
@NP	5 % BSA	11539
@NP	GIBCO	11547
@NP	USA	11554
@NP	30 minutes	11563
@NP	incubation	11586
@NP	Brdu antibody -LRB- Guangzhou RIBOBIO Co. , Ltd. , China -RRB- for 30 minutes	11600
@NP	Brdu antibody -LRB- Guangzhou RIBOBIO Co. , Ltd. , China -RRB-	11600
@NP	Brdu antibody	11600
@NP	Guangzhou RIBOBIO Co.	11615
@NP	Ltd.	11638
@NP	China	11644
@NP	30 minutes	11655
@NP	The slides	11667
@NP	90 % glycerol	11696
@NP	fluorescence microscope -LRB- OLYMPUS , Japan -RRB-	11728
@NP	fluorescence microscope	11728
@NP	OLYMPUS	11753
@NP	Japan	11762
@NP	OECs and BMSCs	11770
@NP	they	11805
@NP	single cell suspension	11853
@NP	The concentration	11877
@NP	104/mL	11911
@NP	bottles	11922
@NP	CO2 incubator	11945
@NP	medium	11960
@NP	every 3 to 4 days	11980
@NP	slides	12004
@NP	more than 60 %	12024
@NP	identification	12047
@NP	steps	12082
@NP	Viability of OECs , BMSCs , and coculture cells	12089
@NP	Viability	12089
@NP	OECs , BMSCs , and coculture cells	12102
@NP	WST-8 cell counting kit -LRB- CCK-8 , DOJINDO , Japan -RRB-	12154
@NP	WST-8 cell counting kit	12154
@NP	CCK-8	12179
@NP	DOJINDO	12186
@NP	Japan	12195
@NP	The assay	12203
@NP	the manufacturer 's instruction with slight modifications	12240
@NP	the manufacturer 's instruction	12240
@NP	the manufacturer 's	12240
@NP	slight modifications	12276
@NP	cells at 2 × 104/mL	12307
@NP	cells	12307
@NP	2 × 104/mL	12316
@NP	a well of a 96-well plate	12344
@NP	a well	12344
@NP	a 96-well plate	12354
@NP	90 per well	12373
@NP	90	12373
@NP	different time periods -LRB- 2 , 4 , 6 , 8 , 10 , and 12 days -RRB-	12406
@NP	different time periods	12406
@NP	2 , 4 , 6 , 8 , 10 , and 12 days	12430
@NP	2	12430
@NP	4	12433
@NP	6	12436
@NP	8	12439
@NP	10	12442
@NP	12 days	12450
@NP	the end of each incubation time	12463
@NP	the end	12463
@NP	each incubation time	12474
@NP	the cells	12496
@NP	addition	12521
@NP	10 CCK-8 solution in each well followed by incubation for 1 h at 37 ∘ C.	12533
@NP	10 CCK-8 solution	12533
@NP	each well followed by incubation for 1 h at 37 ∘ C.	12558
@NP	each	12558
@NP	incubation for 1 h	12580
@NP	incubation	12580
@NP	1 h	12595
@NP	37 ∘ C.	12602
@NP	37 ∘	12602
@NP	C.	12605
@NP	Optical density at 450 nm	12608
@NP	Optical density	12608
@NP	450 nm	12627
@NP	a microplate reader -LRB- Thermo Fisher , USA -RRB-	12650
@NP	a microplate reader	12650
@NP	Thermo Fisher	12671
@NP	USA	12686
@NP	Each experiment	12692
@NP	triplicate	12725
@NP	three times	12763
@NP	Cell viability	12776
@NP	the growth rate with respect	12808
@NP	the growth rate	12808
@NP	respect	12829
@NP	the cell number of the day	12840
@NP	the cell number	12840
@NP	the day	12859
@NP	2.4	12868
@NP	Transplantation	12873
@NP	BMSCs	13360
@NP	a concentration of 1 × 106 cells/100 , which were used for transplantation	13386
@NP	a concentration	13386
@NP	1 × 106 cells/100 , which were used for transplantation	13405
@NP	1 × 106 cells/100	13405
@NP	transplantation	13448
@NP	Rats	13465
@NP	7 days	13487
@NP	SCI	13506
@NP	the rats	13515
@NP	transplantation	13546
@NP	aHamilton syringe	13582
@NP	Sigma	13601
@NP	USA	13608
@NP	a microinjector	13635
@NP	a customized needle with a sterile 30-gauge needle	13659
@NP	a customized needle	13659
@NP	a sterile 30-gauge needle	13684
@NP	A small hole	13711
@NP	the dura at the injection site.Then	13736
@NP	the dura	13736
@NP	the injection site.Then	13748
@NP	the customized needle	13773
@NP	the spinal cord at the midline	13813
@NP	the spinal cord	13813
@NP	the midline	13832
@NP	a depth of 1 to 1.5 mm	13847
@NP	a depth	13847
@NP	1 to 1.5 mm	13858
@NP	30 cell suspension at 1 × 106 cells/100 of the cell suspension	13871
@NP	30 cell suspension	13871
@NP	1 × 106 cells/100 of the cell suspension	13897
@NP	1 × 106 cells/100	13897
@NP	the cell suspension	13922
@NP	2 minutes	13965
@NP	The needle	13976
@NP	place for 2 minutes	13999
@NP	place	13999
@NP	2 minutes	14009
@NP	injection	14025
@NP	withdrawal	14042
@NP	cell leakage	14065
@NP	The OECs and the combination of OECs and BMSCs	14079
@NP	The OECs	14079
@NP	the combination of OECs and BMSCs	14092
@NP	the combination	14092
@NP	OECs and BMSCs	14111
@NP	the spinal cord in the same manner	14149
@NP	the spinal cord	14149
@NP	the same manner	14168
@NP	the combination of OECs and BMSCs	14189
@NP	the combination	14189
@NP	OECs and BMSCs	14208
@NP	the spinal cord with 15 BMSCs cell suspension	14245
@NP	the spinal cord	14245
@NP	15 BMSCs cell suspension	14266
@NP	1 × 106 cells/100 suspensionat 1 × 106 cells/100	14297
@NP	1 ×	14297
@NP	106 cells/100 suspensionat 1 × 106 cells/100	14301
@NP	106 cells/100 suspensionat	14301
@NP	1 × 106 cells/100	14345
@NP	The sham group	14368
@NP	DMEM culture medium and serum `` transplanted '' in the same way	14387
@NP	DMEM culture medium	14387
@NP	serum `` transplanted '' in the same way	14411
@NP	serum	14411
@NP	the same way	14435
@NP	2.5	14449
@NP	Histopathological Examination .	14454
@NP	14 and 28 days posttransplantation , ratswere deeply anesthetized	14485
@NP	14 and 28 days posttransplantation , ratswere	14485
@NP	14 and 28 days	14485
@NP	posttransplantation	14500
@NP	ketamine	14555
@NP	xylazine	14565
@NP	The spinal cord tissues	14575
@NP	a razor blade	14630
@NP	10 % -LRB- v/v -RRB-	14662
@NP	10 %	14662
@NP	v/v	14666
@NP	neutral phosphate-buffered formalin solution	14671
@NP	The tissues	14717
@NP	paraffin blocks	14746
@NP	5 slice	14778
@NP	the glass slides	14807
@NP	hematoxylin and eosin -LRB- H&E -RRB- for histopathological evaluation	14842
@NP	hematoxylin and eosin -LRB- H&E -RRB-	14842
@NP	hematoxylin and eosin	14842
@NP	H&E	14865
@NP	histopathological evaluation	14874
@NP	the lightmicroscope -LRB- LeicaDM4000M , Germany -RRB-	14909
@NP	the lightmicroscope	14909
@NP	LeicaDM4000M	14930
@NP	Germany	14943
@NP	the photos	14956
@NP	optical microscope -LRB- Leica DM4000M , Germany -RRB-	14984
@NP	optical microscope	14984
@NP	Leica DM4000M	15004
@NP	Germany	15019
@NP	The identity and analysis of the pathology sections	15028
@NP	The identity and analysis	15028
@NP	the pathology sections	15057
@NP	the pathologists	15094
@NP	the results	15116
@NP	other certified veterinary pathologists	15149
@NP	other	15149
@NP	veterinary pathologists	15165
@NP	2.6	15190
@NP	Detection of Apoptosis .	15195
@NP	Detection	15195
@NP	Apoptosis	15208
@NP	14 and 28 days after transplantation , rats	15219
@NP	14 and 28 days	15219
@NP	transplantation , rats	15240
@NP	transplantation	15240
@NP	rats	15257
@NP	ketamine/xylazine	15292
@NP	The spinal cord tissues of the rats	15311
@NP	The spinal cord tissues	15311
@NP	the rats	15338
@NP	a terminal deoxynucleotide transferase dUTP nick end labeling -LRB- TUNEL -RRB-	15375
@NP	a terminal deoxynucleotide transferase dUTP nick end labeling	15375
@NP	TUNEL	15438
@NP	cell death detection kit	15459
@NP	the manufacturer 's instructions	15497
@NP	the manufacturer 's	15497
@NP	Chemicon International Inc.	15530
@NP	Temecula	15559
@NP	CA	15569
@NP	rats -LRB- = 4 -RRB- from normal control , treated , and sham control groups	15583
@NP	rats -LRB- = 4 -RRB-	15583
@NP	rats	15583
@NP	= 4	15592
@NP	normal control , treated , and sham control groups	15602
@NP	normal control , treated ,	15602
@NP	normal control	15602
@NP	sham control groups	15631
@NP	4 % paraformaldehyde in 0.1 M phosphate buffer -LRB- pH 7.4 -RRB-	15676
@NP	4 % paraformaldehyde	15676
@NP	0.1 M phosphate buffer -LRB- pH 7.4 -RRB-	15699
@NP	0.1 M phosphate buffer	15699
@NP	pH 7.4	15722
@NP	the sections	15736
@NP	proteinase K -LRB- 100 / mL -RRB-	15769
@NP	proteinase K	15769
@NP	100	15783
@NP	mL	15791
@NP	3 % H2O2	15817
@NP	andwashedwith PBS for 10 min followed by washing with permeabilization solution	15825
@NP	andwashedwith PBS	15825
@NP	10 min	15847
@NP	permeabilization solution	15878
@NP	0.1 % Triton X-100 , 0.1 % sodium citrate	15905
@NP	0.1 % Triton X-100	15905
@NP	0.1 % sodium citrate	15924
@NP	5 min	15949
@NP	the sections	15961
@NP	PBS	15997
@NP	TUNEL reactionmixture	16015
@NP	they	16056
@NP	converter-PODwith 0.02 % 3,3 - diaminobenzidine -LRB- DAB -RRB-	16083
@NP	0.02 % 3,3 - diaminobenzidine -LRB- DAB -RRB-	16101
@NP	0.02 % 3,3	16101
@NP	0.02 %	16101
@NP	3,3	16106
@NP	diaminobenzidine -LRB- DAB -RRB-	16112
@NP	diaminobenzidine	16112
@NP	DAB	16130
@NP	Mayer 's hematoxylin	16136
@NP	Mayer 's	16136
@NP	counter-staining	16169
@NP	The sections	16187
@NP	gelatin-coated slides	16226
@NP	they	16257
@NP	air-dried overnight at room temperature	16267
@NP	air-dried overnight	16267
@NP	room temperature	16290
@NP	Yellow stained nucleus	16308
@NP	Yellow	16308
@NP	nucleus	16323
@NP	TUNEL-positive cells	16335
@NP	TUNEL-positive cell quantitative method	16357
@NP	TUNEL-positive cell	16357
@NP	quantitative method	16377
@NP	each group	16410
@NP	5 cases of well-stained sections	16422
@NP	5 cases	16422
@NP	well-stained sections	16433
@NP	10 times for observation	16483
@NP	10 times	16483
@NP	observation	16496
@NP	the microscope objective	16514
@NP	5 high power fields -LRB- × 400 -RRB-	16540
@NP	5 high power fields	16540
@NP	× 400	16561
@NP	each sectionwere randomly selected , and a total of 25 high power fields	16570
@NP	each sectionwere randomly selected	16570
@NP	each sectionwere	16570
@NP	a total of 25 high power fields	16610
@NP	a total	16610
@NP	25 high power fields	16621
@NP	computer -LRB- resolution is 800 × 600 -RRB-	16665
@NP	computer	16665
@NP	resolution	16675
@NP	800 × 600	16689
@NP	800 ×	16689
@NP	600	16695
@NP	Q550CW image signal acquisition and analysis system	16701
@NP	Q550CW image signal acquisition	16701
@NP	analysis system	16737
@NP	intestinal epithelial cell apoptosis index	16779
@NP	The number of apoptotic cells/the total cell number × 100 %	16823
@NP	The number	16823
@NP	apoptotic cells/the total cell number × 100 %	16837
@NP	apoptotic cells/the total cell number	16837
@NP	the apoptosis rate of this field	16888
@NP	the apoptosis rate	16888
@NP	this field	16910
@NP	the average rate of apoptosis of five fields	16926
@NP	the average rate	16926
@NP	apoptosis of five fields	16946
@NP	apoptosis	16946
@NP	five fields	16959
@NP	the apoptosis rate of rat spinal cord cells in the group	16975
@NP	the apoptosis rate	16975
@NP	rat spinal cord cells	16997
@NP	the group	17022
@NP	2.7	17033
@NP	Western Blot Assay .	17038
@NP	Western Blot	17038
@NP	Assay	17051
@NP	Western blot	17058
@NP	protein expression of Bax , Bcl-2 , Caspase-9 , and Caspase-3	17090
@NP	protein expression	17090
@NP	Bax , Bcl-2 , Caspase-9 , and Caspase-3	17112
@NP	Bax	17112
@NP	Bcl-2 , Caspase-9 , and Caspase-3	17117
@NP	transplantation -LRB- OECs , BMSCs , and OECs and BMSCs , resp . -RRB-	17175
@NP	transplantation	17175
@NP	OECs , BMSCs , and OECs and BMSCs , resp	17192
@NP	OECs	17192
@NP	BMSCs	17198
@NP	OECs and BMSCs , resp	17209
@NP	OECs and BMSCs	17209
@NP	resp	17225
@NP	14 days and 28 days	17236
@NP	14 days	17236
@NP	28 days	17248
@NP	rats	17257
@NP	5 mm lengths of spinal cord centered on T10	17283
@NP	5 mm lengths	17283
@NP	spinal cord centered on T10	17298
@NP	spinal cord	17298
@NP	T10	17322
@NP	−	17371
@NP	70 ∘ C	17372
@NP	necessary for further experimentation.The tissues	17383
@NP	further experimentation.The	17397
@NP	0.2 mL	17469
@NP	homogenization buffer	17478
@NP	centrifuge for 10 min -LRB- 12,000 r/min , at 4 ∘ C -RRB-	17512
@NP	centrifuge	17512
@NP	10 min -LRB- 12,000 r/min , at 4 ∘ C -RRB-	17527
@NP	10 min	17527
@NP	12,000 r/min , at 4 ∘ C	17535
@NP	12,000 r/min	17535
@NP	4 ∘ C	17552
@NP	The supernatants	17558
@NP	protein determination	17594
@NP	Protein samples -LRB- 50 -RRB-	17617
@NP	Protein samples	17617
@NP	50	17634
@NP	SDSPAGE	17660
@NP	12 %	17669
@NP	gels , 5 % stacking gels	17683
@NP	gels	17683
@NP	gels	17701
@NP	PVDF membranes -LRB- 150 mA , 1.5 h -RRB-	17726
@NP	PVDF membranes	17726
@NP	150 mA , 1.5 h	17742
@NP	150 mA	17742
@NP	1.5 h	17750
@NP	Millipore Corporation	17758
@NP	USA	17781
@NP	5 % nonfat dry milk , the membraneswere incubatedwith	17807
@NP	5 % nonfat dry milk	17807
@NP	the membraneswere incubatedwith	17827
@NP	different primary antibodies	17859
@NP	anti-Bax , anti-Bcl-2 -LRB- Abcam , USA -RRB- , anti-Caspase	17898
@NP	anti-Bax	17898
@NP	anti-Bcl-2	17908
@NP	Abcam	17920
@NP	USA	17927
@NP	9 , anti-Caspase-3	17947
@NP	9	17947
@NP	anti-Caspase-3	17950
@NP	anti-GAPDH -LRB- Sigma , USA -RRB- overnight at 4 ∘ C.	17970
@NP	anti-GAPDH -LRB- Sigma , USA -RRB- overnight	17970
@NP	Sigma	17982
@NP	USA	17989
@NP	4 ∘ C.	18007
@NP	4 ∘	18007
@NP	C.	18009
@NP	washingmembranes with TBST	18018
@NP	washingmembranes	18018
@NP	TBST	18040
@NP	the membranes	18046
@NP	goat anti-mouse IgG-HRP	18080
@NP	secondary antibody -LRB- Sigma , USA -RRB- at a 1 : 1000 dilution for 1.5 h	18115
@NP	secondary antibody -LRB- Sigma , USA -RRB- at a 1	18115
@NP	secondary antibody -LRB- Sigma , USA -RRB-	18115
@NP	secondary antibody	18115
@NP	Sigma	18135
@NP	USA	18142
@NP	a 1	18150
@NP	1000 dilution for 1.5 h	18156
@NP	1000 dilution	18156
@NP	1.5 h	18174
@NP	roomtemperature	18183
@NP	the proteinswere	18209
@NP	an enhanced chemiluminescence detection system	18243
@NP	ECL detection kit , Pierce	18291
@NP	ECL detection kit	18291
@NP	Pierce	18310
@NP	The membranes	18319
@NP	AR film -LRB- Eastman Kodak Company , USA -RRB-	18355
@NP	AR film	18355
@NP	Eastman Kodak Company	18364
@NP	USA	18387
@NP	the results	18396
@NP	densitometric analysis -LRB- MAISIQI HIGH-TECH Co. , Ltd , MSD-26 , China -RRB-	18432
@NP	densitometric analysis	18432
@NP	MAISIQI HIGH-TECH Co. , Ltd , MSD-26 , China	18456
@NP	MAISIQI HIGH-TECH Co.	18456
@NP	Ltd	18479
@NP	MSD-26	18484
@NP	China	18492
@NP	Experiments	18500
@NP	triplicate	18530
@NP	reproducibility	18551
@NP	2.8	18568
@NP	Behavioral Assessment after SCI .	18573
@NP	Behavioral Assessment	18573
@NP	SCI	18601
@NP	The recovery of gross motor function	18606
@NP	The recovery	18606
@NP	gross motor function	18622
@NP	Basso , Beattie , and Bresnahan -LRB- BBB -RRB- locomotor rating scale	18663
@NP	Basso	18663
@NP	Beattie	18670
@NP	Bresnahan -LRB- BBB -RRB- locomotor rating scale	18683
@NP	Bresnahan	18683
@NP	BBB	18694
@NP	locomotor rating scale	18699
@NP	the procedure described in Basso et al. -LSB- 26 -RSB-	18732
@NP	the procedure	18732
@NP	Basso et al. -LSB- 26 -RSB-	18759
@NP	Basso et al. -LSB-	18759
@NP	The scale used for measuring hind limb function with these procedures	18778
@NP	The scale	18778
@NP	hind limb function	18807
@NP	these procedures	18831
@NP	complete paralysis -LRB- score 0 -RRB- to normal gait -LRB- score 21 -RRB-	18860
@NP	complete paralysis -LRB- score 0 -RRB-	18860
@NP	complete paralysis	18860
@NP	score 0	18880
@NP	normal gait -LRB- score 21 -RRB-	18892
@NP	normal gait	18892
@NP	score 21	18905
@NP	an increasing score	18921
@NP	the degree in use of individual joints	18952
@NP	the degree	18952
@NP	use of individual joints	18966
@NP	use	18966
@NP	individual joints	18973
@NP	weight-bearing	18992
@NP	limb movement	19020
@NP	joint movement	19047
@NP	other functions	19067
@NP	Locomotion	19084
@NP	digital video camera at each time point	19111
@NP	digital video camera	19111
@NP	each time point	19135
@NP	two blind researchers	19167
@NP	Rats	19190
@NP	the open field for the test	19224
@NP	the open field	19224
@NP	the test	19243
@NP	a rat	19259
@NP	the open field , two investigators conducted	19292
@NP	the open field	19292
@NP	two investigators conducted	19308
@NP	two investigators	19308
@NP	4-minute testing sessions on each leg	19336
@NP	4-minute testing sessions	19336
@NP	each leg	19365
@NP	Two individuals `` blinded '' to rat treatment status	19375
@NP	Two individuals	19375
@NP	rat treatment status	19404
@NP	the open field test at least once a week	19435
@NP	the open field test	19435
@NP	once a week	19464
@NP	day 1	19481
@NP	SCI	19493
@NP	4 weeks -LRB- 1 , 7 , 8 , 10 , 14 , 21 , 28 , and 35 days after SCI -RRB-	19500
@NP	1 , 7 , 8 , 10 , 14 , 21 , 28 , and 35 days after SCI	19509
@NP	1	19509
@NP	7	19512
@NP	8	19515
@NP	10	19518
@NP	14	19522
@NP	21	19526
@NP	28	19530
@NP	35 days after SCI	19538
@NP	35 days	19538
@NP	SCI	19552
@NP	laminectomy for all animals in the study	19563
@NP	laminectomy	19563
@NP	all animals in the study	19579
@NP	all animals	19579
@NP	the study	19594
@NP	Behavioral outcomes and examples of specific BBB locomotor scores	19605
@NP	Behavioral outcomes and examples	19605
@NP	specific BBB locomotor scores	19641
@NP	digital video	19691
@NP	2.9	19706
@NP	Statistical Analysis .	19711
@NP	Quantitative data	19733
@NP	open field locomotor scores , detection of apoptosis , and Western blot analysis	19756
@NP	open field locomotor scores	19756
@NP	detection of apoptosis	19785
@NP	detection	19785
@NP	apoptosis	19798
@NP	Western blot analysis	19813
@NP	statistical significance	19854
@NP	one-way Analysis of Variance -LRB- ANOVA -RRB-	19882
@NP	one-way Analysis	19882
@NP	Variance -LRB- ANOVA -RRB-	19902
@NP	Variance	19902
@NP	ANOVA	19912
@NP	replications	19924
@NP	Data for each group	19938
@NP	Data	19938
@NP	each group	19947
@NP	mean ± SD	19978
@NP	other groups for significance	20006
@NP	other groups	20006
@NP	significance	20023
@NP	ANOVA	20039
@NP	least significant difference -LRB- LSD -RRB- test	20057
@NP	LSD	20087
@NP	the differences between groups	20108
@NP	the differences	20108
@NP	groups	20132
@NP	Results	20140
@NP	Results Table 1	20208
@NP	Results	20208
@NP	Table 1	20216
@NP	The change of body weight for rats after surgery -LRB- g , ± SD -RRB-	20224
@NP	The change	20224
@NP	body weight for rats after surgery -LRB- g , ± SD -RRB-	20238
@NP	body weight	20238
@NP	rats after surgery -LRB- g , ± SD -RRB-	20254
@NP	rats	20254
@NP	surgery -LRB- g , ± SD -RRB-	20265
@NP	surgery	20265
@NP	g , ± SD	20274
@NP	g	20274
@NP	± SD	20280
@NP	Table 2	20288
@NP	BBB scores	20297
@NP	rats	20311
@NP	SCI before transplantation at 1 day and 7 days after SCI -LRB- ± SD -RRB-	20321
@NP	SCI	20321
@NP	transplantation at 1 day and 7 days after SCI -LRB- ± SD -RRB-	20332
@NP	transplantation at 1 day	20332
@NP	transplantation	20332
@NP	1 day	20351
@NP	7 days after SCI -LRB- ± SD -RRB-	20361
@NP	7 days	20361
@NP	SCI -LRB- ± SD -RRB-	20374
@NP	SCI	20374
@NP	± SD	20382
@NP	Table 3	20390
@NP	BBB scores	20399
@NP	rats with SCI after OECs and MSCs transplantation treatments -LRB- ± SD -RRB-	20413
@NP	rats	20413
@NP	SCI after OECs and MSCs transplantation treatments -LRB- ± SD -RRB-	20423
@NP	SCI	20423
@NP	OECs and MSCs transplantation treatments -LRB- ± SD -RRB-	20433
@NP	OECs and MSCs transplantation treatments	20433
@NP	± SD	20478
@NP	Figure 3 : The growth curve of OECs , BMSCs , and coculture cells .	20486
@NP	Figure 3	20486
@NP	The growth curve of OECs , BMSCs , and coculture cells	20496
@NP	The growth curve	20496
@NP	OECs , BMSCs , and coculture cells	20516
@NP	Figure 1	20551
@NP	Animal experimental design	20561
@NP	antiapoptotic effects of cotransplantation of OECs and BMSCs in adult rats	20591
@NP	antiapoptotic effects	20591
@NP	cotransplantation of OECs and BMSCs in adult rats	20616
@NP	cotransplantation	20616
@NP	OECs and BMSCs in adult rats	20637
@NP	OECs and BMSCs	20637
@NP	adult rats	20655
@NP	Figure 2	20668
@NP	Morphological features ofOECs , BMSCs , and coculture cells -LRB- × 200 -RRB-	20677
@NP	Morphological features ofOECs	20677
@NP	BMSCs	20708
@NP	coculture cells -LRB- × 200 -RRB-	20719
@NP	coculture cells	20719
@NP	× 200	20736
@NP	OECs	20742
@NP	bipolar andmultipolar , woven into a net -LRB- a -RRB-	20752
@NP	bipolar andmultipolar	20752
@NP	a net -LRB- a -RRB-	20786
@NP	a net	20786
@NP	OECs	20796
@NP	p75NTR -LRB- green , b -RRB-	20822
@NP	p75NTR	20822
@NP	green , b	20830
@NP	green	20830
@NP	b	20837
@NP	BMSCs	20841
@NP	the shape	20864
@NP	spindle -LRB- c -RRB-	20883
@NP	spindle	20883
@NP	c	20892
@NP	Brdu	20896
@NP	the cell core -LRB- red , d -RRB-	20923
@NP	the cell core	20923
@NP	red , d	20938
@NP	red	20938
@NP	d	20943
@NP	The coculture cells , OECs	20947
@NP	the cell membrane	20992
@NP	green	21011
@NP	and cell	21021
@NP	core -LRB- yellow , e -RRB-	21030
@NP	core	21030
@NP	yellow	21036
@NP	e	21044
@NP	-LRB- red arrow -RRB-	21047
@NP	BMSCs	21060
@NP	the cell core	21085
@NP	red , f -RRB- -LRB- white arrow -RRB- and not in the cell membrane -LRB- green ,	21100
@NP	red	21100
@NP	f -RRB- -LRB- white arrow -RRB- and not in the cell membrane -LRB- green ,	21105
@NP	-LRB- white arrow -RRB-	21108
@NP	not in the cell membrane -LRB- green ,	21126
@NP	not in the cell membrane	21126
@NP	not	21126
@NP	the cell membrane	21133
@NP	green	21152
@NP	Figure 5	21164
@NP	Cellular apoptosis	21174
@NP	spinal cord injury	21199
@NP	OECs and BMSCs -LRB- TUNEL staining , 10 × 40 -RRB-	21233
@NP	OECs and BMSCs	21233
@NP	TUNEL staining , 10 × 40	21249
@NP	TUNEL staining	21249
@NP	10 × 40	21265
@NP	10 ×	21265
@NP	40	21270
@NP	-LRB- A -RRB-	21281
@NP	14 days	21285
@NP	transplantation	21299
@NP	-LRB- B -RRB- 28 days after transplantation ; -LRB- a1 , a2 -RRB- control group	21316
@NP	-LRB- B -RRB-	21316
@NP	28 days after transplantation ; -LRB- a1 , a2 -RRB- control group	21320
@NP	28 days	21320
@NP	transplantation	21334
@NP	a1 , a2	21352
@NP	a1	21352
@NP	a2	21356
@NP	b1 , b2	21376
@NP	b1	21376
@NP	b2	21380
@NP	sham group	21384
@NP	-LRB- c1 , c2 -RRB- OECs	21396
@NP	c1 , c2	21397
@NP	c1	21397
@NP	c2	21401
@NP	group ; -LRB- d1 , d2 -RRB- BMSCs treated group ; -LRB- e1 , e2 -RRB-	21418
@NP	group ; -LRB- d1 , d2 -RRB- BMSCs treated group ;	21418
@NP	group	21418
@NP	-LRB- d1 , d2 -RRB- BMSCs treated group	21425
@NP	-LRB- d1 , d2 -RRB- BMSCs	21425
@NP	d1 , d2	21426
@NP	d1	21426
@NP	d2	21430
@NP	group	21448
@NP	e1 , e2	21456
@NP	e1	21456
@NP	e2	21460
@NP	cotransplant treated group	21464
@NP	-LRB- C -RRB- The spinal cord cell apoptosis rate of rats in each group .	21492
@NP	The spinal cord cell apoptosis rate	21495
@NP	rats in each group	21534
@NP	rats	21534
@NP	each group	21542
@NP	a < 0.05 versus control group	21554
@NP	a < 0.05	21554
@NP	control group	21573
@NP	b < 0.05 versus sham group ; c < 0.05	21588
@NP	b < 0.05 versus sham group ; c <	21588
@NP	0.05	21594
@NP	sham group ; c	21606
@NP	sham group	21606
@NP	c	21618
@NP	0.05	21625
@NP	OECs treated group ; and d < 0.05 versus BMSCs treated group	21637
@NP	OECs treated group ; and d < 0.05	21637
@NP	OECs	21637
@NP	group	21650
@NP	<	21666
@NP	BMSCs treated group	21680
@NP	BMSCs	21680
@NP	group	21694
@NP	Figure 6	21702
@NP	The expression	21711
@NP	Bax , Bcl-2 , Caspase-9 , Caspase-3 , and GADPH protein	21729
@NP	spinal cord 14 days and 28 days after transplantation	21784
@NP	spinal cord 14 days	21784
@NP	spinal cord	21784
@NP	14 days	21796
@NP	28 days after transplantation	21808
@NP	28 days	21808
@NP	transplantation	21822
@NP	Western blot analysis	21842
@NP	Bax , Bcl-2 , Caspase-9 , Caspase-3 , andGADPHproteins of spinal cord	21867
@NP	Bax	21867
@NP	Bcl-2	21872
@NP	Caspase-9	21878
@NP	Caspase-3	21888
@NP	andGADPHproteins of spinal cord	21899
@NP	andGADPHproteins	21899
@NP	spinal cord	21919
@NP	-LRB- b -RRB- Relative ratio of Bax protein .	21932
@NP	Relative ratio	21936
@NP	Bax protein	21954
@NP	-LRB- c -RRB- Relative ratio of Bcl-2 protein .	21967
@NP	Relative ratio	21971
@NP	Bcl-2 protein	21989
@NP	-LRB- d -RRB- Relative ratio of Caspase-9 protein .	22004
@NP	Relative ratio	22008
@NP	Caspase-9 protein	22026
@NP	-LRB- e -RRB- Relative ratio of Caspase-3 protein .	22045
@NP	Relative ratio	22049
@NP	Caspase-3 protein	22067
@NP	a < 0.05 versus control group	22086
@NP	a < 0.05	22086
@NP	control group	22105
@NP	b < 0.05 versus sham group ; c < 0.05	22120
@NP	b < 0.05 versus sham group ; c <	22120
@NP	0.05	22127
@NP	sham group ; c	22139
@NP	sham group	22139
@NP	c	22151
@NP	0.05	22158
@NP	OECs treated group ; and d < 0.05 versus BMSCs treated group	22170
@NP	OECs treated group ; and d < 0.05	22170
@NP	OECs	22170
@NP	group	22183
@NP	<	22199
@NP	BMSCs treated group	22213
@NP	BMSCs	22213
@NP	group	22227
@NP	3.1	22235
@NP	Culture and Identification of Stem Cells .	22240
@NP	Culture and Identification	22240
@NP	Stem Cells	22270
@NP	microcode	22288
@NP	theOECswerebipolar ormultipolar andcellprotrusion	22299
@NP	a net on the fifth day	22386
@NP	a net	22386
@NP	the fifth day	22395
@NP	The OECs	22410
@NP	positive staining -LRB- green , under fluorescent microscope -RRB-	22438
@NP	positive staining	22438
@NP	green , under fluorescent microscope	22457
@NP	green	22457
@NP	fluorescent microscope	22470
@NP	p75 antibody -LRB- Figures 2 -LRB- a -RRB- and 2 -LRB- b -RRB- -RRB-	22499
@NP	p75 antibody	22499
@NP	Figures 2 -LRB- a -RRB- and 2 -LRB- b -RRB-	22513
@NP	Figures	22513
@NP	2 -LRB- a -RRB- and 2 -LRB- b -RRB-	22521
@NP	2 -LRB- a -RRB-	22521
@NP	2	22521
@NP	a	22523
@NP	2 -LRB- b -RRB-	22530
@NP	2	22530
@NP	b	22532
@NP	The BMSCs	22537
@NP	the shape of spindle	22554
@NP	the shape	22554
@NP	spindle	22567
@NP	the fifth day	22634
@NP	Immunofluorescence staining with Brdu	22649
@NP	Immunofluorescence staining	22649
@NP	Brdu	22682
@NP	the color of nucleus	22699
@NP	the color	22699
@NP	nucleus	22712
@NP	Figures 2 -LRB- c -RRB- and 2 -LRB- d -RRB-	22729
@NP	Figures	22729
@NP	2 -LRB- c -RRB- and 2 -LRB- d -RRB-	22737
@NP	2 -LRB- c -RRB-	22737
@NP	2 -LRB- d -RRB-	22746
@NP	OECs or BMSCs	22767
@NP	the coculture cells	22782
@NP	complete adherent 24 h	22807
@NP	24	22825
@NP	protrusion	22841
@NP	fifth day	22866
@NP	coculture cells	22876
@NP	bipolar triode or multipolar one	22923
@NP	bipolar triode	22923
@NP	multipolar one	22941
@NP	the OECs or BMSCs	22961
@NP	protrusion	22994
@NP	The cells with green cell membrane and yellow cell nuclear	23018
@NP	The cells	23018
@NP	green cell membrane and yellow cell nuclear	23033
@NP	green cell membrane	23033
@NP	yellow cell nuclear	23057
@NP	OECs	23082
@NP	cells with red nuclear	23092
@NP	cells	23092
@NP	red nuclear	23103
@NP	BMSCs	23120
@NP	green cell membrane	23134
@NP	There	23155
@NP	much difference	23169
@NP	rate	23188
@NP	these two kinds of cells -LRB- Figures 2 -LRB- e -RRB- and 2 -LRB- f -RRB- -RRB-	23196
@NP	these two kinds	23196
@NP	cells -LRB- Figures 2 -LRB- e -RRB- and 2 -LRB- f -RRB- -RRB-	23215
@NP	cells	23215
@NP	Figures 2 -LRB- e -RRB- and 2 -LRB- f -RRB-	23222
@NP	Figures	23222
@NP	2 -LRB- e -RRB- and 2 -LRB- f -RRB-	23230
@NP	2 -LRB- e -RRB-	23230
@NP	2	23230
@NP	e	23232
@NP	2 -LRB- f -RRB-	23239
@NP	2	23239
@NP	f	23241
@NP	The membrane and cell protrusion of OECs	23246
@NP	The membrane and cell protrusion	23246
@NP	OECs	23282
@NP	fluorescence	23304
@NP	the cells shape	23318
@NP	bipolar triode and multipolar model	23341
@NP	Figures 2 -LRB- a -RRB- and 2 -LRB- b -RRB-	23378
@NP	Figures	23378
@NP	2 -LRB- a -RRB- and 2 -LRB- b -RRB-	23386
@NP	2 -LRB- a -RRB-	23386
@NP	2	23386
@NP	a	23388
@NP	2 -LRB- b -RRB-	23395
@NP	2	23395
@NP	b	23397
@NP	the BMSCs shape	23406
@NP	spindle	23426
@NP	the fifth day	23493
@NP	the shape	23508
@NP	the spindle	23533
@NP	the growth direction	23550
@NP	Immunofluorescence staining	23584
@NP	the color of nucleus	23619
@NP	the color	23619
@NP	nucleus	23632
@NP	Figures 2 -LRB- c -RRB- and 2 -LRB- d -RRB-	23649
@NP	Figures	23649
@NP	2 -LRB- c -RRB- and 2 -LRB- d -RRB-	23657
@NP	2 -LRB- c -RRB-	23657
@NP	2 -LRB- d -RRB-	23666
@NP	We	23673
@NP	the morphology observation and identification of coculture cells	23680
@NP	the morphology observation and identification	23680
@NP	coculture cells	23729
@NP	Cells	23746
@NP	complete adherent 24 h	23757
@NP	24	23775
@NP	protrusion	23791
@NP	fifth day	23816
@NP	cells	23826
@NP	bipolar triode or multipolar model	23863
@NP	bipolar triode	23863
@NP	multipolar model	23881
@NP	other cells	23899
@NP	protrusion	23927
@NP	The positive cells with green cell membrane and yellow cell nuclear	23951
@NP	The positive cells	23951
@NP	green cell membrane and yellow cell nuclear	23975
@NP	green cell membrane	23975
@NP	yellow cell nuclear	23999
@NP	OECs	24024
@NP	cells with red nuclear	24030
@NP	cells	24030
@NP	red nuclear	24041
@NP	BMSCs	24058
@NP	green cell membrane.The rate	24072
@NP	two kinds	24104
@NP	cells was not different significantly	24117
@NP	cells	24117
@NP	Figures 2 -LRB- e -RRB- and 2 -LRB- f -RRB-	24156
@NP	Figures	24156
@NP	2 -LRB- e -RRB- and 2 -LRB- f -RRB-	24164
@NP	2 -LRB- e -RRB-	24164
@NP	2	24164
@NP	e	24166
@NP	2 -LRB- f -RRB-	24173
@NP	2	24173
@NP	f	24175
@NP	3.2	24180
@NP	The Viability of OECs , BMSCs , and Coculture Cells .	24185
@NP	The Viability	24185
@NP	OECs , BMSCs , and Coculture Cells	24202
@NP	All cells	24236
@NP	similar growth rate	24253
@NP	Lowproliferation of the cells	24274
@NP	Lowproliferation	24274
@NP	the cells	24294
@NP	the first two days	24317
@NP	it	24340
@NP	day 2	24359
@NP	day 6 after which it maintained the similar level as shown in Figure 1	24368
@NP	day 6	24368
@NP	it	24386
@NP	the similar level	24400
@NP	Figure 1	24430
@NP	the growth curve of OECs and BMSCs	24458
@NP	the growth curve	24458
@NP	OECs and BMSCs	24478
@NP	the coculture cells curve	24494
@NP	Figure 3	24549
@NP	3.3	24560
@NP	The Change of Body Weight for Rats after Surgery .	24565
@NP	The Change	24565
@NP	Body Weight for Rats	24579
@NP	Body Weight	24579
@NP	Rats	24595
@NP	Surgery	24606
@NP	All the rats	24615
@NP	2 -- 4 hours after surgery	24643
@NP	2	24643
@NP	4 hours after surgery	24645
@NP	4 hours	24645
@NP	surgery	24659
@NP	6 hours	24698
@NP	surgery	24712
@NP	The rats ' diet	24721
@NP	The rats '	24721
@NP	normal after three day postsurgery	24748
@NP	three day	24761
@NP	The body weight of rats in the control group	24784
@NP	The body weight	24784
@NP	rats in the control group	24803
@NP	rats	24803
@NP	the control group	24811
@NP	the observation period	24860
@NP	the body weight of rats in the sham group , OECs treated group	24888
@NP	the body weight	24888
@NP	rats in the sham group , OECs treated group	24907
@NP	rats	24907
@NP	the sham group , OECs treated group	24915
@NP	the sham group	24915
@NP	OECs treated group	24931
@NP	OECs	24931
@NP	group	24944
@NP	BMSCs treated group	24951
@NP	BMSCs	24951
@NP	group	24965
@NP	cotransplant treated group	24976
@NP	14 days	25019
@NP	surgery -LRB- Table 1 -RRB-	25033
@NP	surgery	25033
@NP	Table 1	25042
@NP	Thebody weight of rats in theOECs treated group	25051
@NP	Thebody weight	25051
@NP	rats in theOECs treated group	25069
@NP	rats	25069
@NP	theOECs treated group	25077
@NP	theOECs	25077
@NP	group	25093
@NP	BMSCs treated group	25100
@NP	BMSCs	25100
@NP	group	25114
@NP	cotransplant treated group	25125
@NP	A significant increase in body weight of rats	25173
@NP	A significant increase	25173
@NP	body weight of rats	25199
@NP	body weight	25199
@NP	rats	25214
@NP	OECs treated group	25232
@NP	OECs	25232
@NP	group	25245
@NP	BMSCs treated group	25252
@NP	BMSCs	25252
@NP	group	25266
@NP	cotransplant treated group compared with that in sham group 14 days	25277
@NP	cotransplant treated group	25277
@NP	that in sham group 14 days	25318
@NP	that	25318
@NP	sham group	25326
@NP	14 days	25337
@NP	28 days after transplantation -LRB- < 0.05 -RRB- -LRB- Table 1 -RRB-	25349
@NP	28 days	25349
@NP	transplantation -LRB- < 0.05 -RRB- -LRB- Table 1 -RRB-	25363
@NP	transplantation -LRB- < 0.05 -RRB-	25363
@NP	transplantation	25363
@NP	< 0.05	25383
@NP	<	25383
@NP	0.05	25385
@NP	Table 1	25392
@NP	The higher body weight of rats	25402
@NP	The higher body weight	25402
@NP	rats	25428
@NP	cotransplant treated group 28 days	25446
@NP	cotransplant treated group	25446
@NP	28 days	25473
@NP	transplantation -LRB- < 0.05 -RRB- -LRB- Table 1 -RRB-	25487
@NP	transplantation -LRB- < 0.05 -RRB-	25487
@NP	transplantation	25487
@NP	< 0.05	25507
@NP	<	25507
@NP	0.05	25509
@NP	Table 1	25516
@NP	the body weight of rats	25530
@NP	the body weight	25530
@NP	rats	25549
@NP	the presurgery level	25574
@NP	the end of the observation period	25601
@NP	the end	25601
@NP	the observation period	25612
@NP	3.4	25636
@NP	Pathology Changes in Spinal Cord Tissue .	25641
@NP	Pathology Changes	25641
@NP	Spinal Cord Tissue	25662
@NP	14 and 28 days after transplantation , no abnormality	25682
@NP	14 and 28 days	25682
@NP	transplantation , no abnormality	25703
@NP	transplantation	25703
@NP	no abnormality	25720
@NP	the control groups	25748
@NP	Black and white matter	25768
@NP	Black	25768
@NP	white matter	25778
@NP	integrity boundaries	25795
@NP	Cavity , liquefaction , and inflammatory cell infiltration	25817
@NP	Cavity	25817
@NP	liquefaction	25825
@NP	inflammatory cell infiltration	25843
@NP	Figure 4 -LRB- A -RRB- , -LRB- a1 -RRB- × 100	25889
@NP	Figure 4 -LRB- A -RRB- , -LRB- a1 -RRB-	25889
@NP	Figure 4 -LRB- A -RRB-	25889
@NP	Figure 4	25889
@NP	A	25898
@NP	a1	25903
@NP	× 100	25907
@NP	Figure 4 -LRB- A -RRB- , -LRB- a -RRB- × 400	25913
@NP	Figure 4 -LRB- A -RRB- , -LRB- a -RRB-	25913
@NP	Figure 4 -LRB- A -RRB-	25913
@NP	Figure 4	25913
@NP	A	25922
@NP	a	25927
@NP	× 400	25930
@NP	Figure 4	25940
@NP	B	25949
@NP	-LRB- a2 -RRB-	25953
@NP	There	25960
@NP	no difference	25970
@NP	spinal cord	25987
@NP	pictures	26007
@NP	14-day groups	26024
@NP	Figure 4 -LRB- A -RRB- , -LRB- a1 -RRB- × 100	26039
@NP	Figure	26039
@NP	4 -LRB- A -RRB- , -LRB- a1 -RRB- × 100	26046
@NP	4 -LRB- A -RRB- , -LRB- a1 -RRB-	26046
@NP	4 -LRB- A -RRB-	26046
@NP	4	26046
@NP	A	26048
@NP	a1	26053
@NP	× 100	26057
@NP	28-day groups	26067
@NP	Figure 4 -LRB- B -RRB- , -LRB- a2 -RRB- × 100	26082
@NP	Figure	26082
@NP	4 -LRB- B -RRB- , -LRB- a2 -RRB- × 100	26089
@NP	4 -LRB- B -RRB- , -LRB- a2 -RRB-	26089
@NP	4 -LRB- B -RRB-	26089
@NP	4	26089
@NP	B	26091
@NP	a2	26096
@NP	× 100	26100
@NP	spinal cord injury	26112
@NP	the spinal cord structure in sham groups	26132
@NP	the spinal cord structure	26132
@NP	sham groups	26161
@NP	The number of cavities induced by spinal cord injury in these three groups	26561
@NP	The number	26561
@NP	cavities induced by spinal cord injury in these three groups	26575
@NP	cavities	26575
@NP	spinal cord injury in these three groups	26595
@NP	spinal cord injury	26595
@NP	these three groups	26617
@NP	that in the sham group 14 days	26650
@NP	that	26650
@NP	the sham group	26658
@NP	14 days	26673
@NP	transplantation	26687
@NP	The cavity	26704
@NP	inducedby spinal cord	26715
@NP	injurywasnosignificant change	26737
@NP	Figure 4 -LRB- B -RRB- , -LRB- b2 -RRB- × 100	26768
@NP	Figure	26768
@NP	4 -LRB- B -RRB- , -LRB- b2 -RRB- × 100	26775
@NP	4 -LRB- B -RRB- , -LRB- b2 -RRB-	26775
@NP	4 -LRB- B -RRB-	26775
@NP	4	26775
@NP	B	26777
@NP	b2	26782
@NP	× 100	26786
@NP	there	26797
@NP	a decrease in the number of the cavities	26807
@NP	a decrease	26807
@NP	the number of the cavities	26821
@NP	the number	26821
@NP	the cavities	26835
@NP	increase	26852
@NP	the number of nerve cells	26864
@NP	the number	26864
@NP	nerve cells	26878
@NP	Figure	26891
@NP	4 -LRB- B -RRB- , -LRB- c2 -RRB- , -LRB- d2 -RRB- , and -LRB- e2 -RRB- × 100	26898
@NP	4 -LRB- B -RRB- , -LRB- c2 -RRB- , -LRB- d2 -RRB- ,	26898
@NP	4 -LRB- B -RRB- , -LRB- c2 -RRB-	26898
@NP	4 -LRB- B -RRB-	26898
@NP	4	26898
@NP	B	26900
@NP	c2	26905
@NP	-LRB- d2 -RRB-	26910
@NP	e2	26921
@NP	× 100	26925
@NP	the most and best obvious change	26942
@NP	the most	26942
@NP	best obvious change	26955
@NP	the cotransplant	26982
@NP	group -LRB- Figure 4 -LRB- B -RRB- , -LRB- e2 -RRB- × 100 -RRB-	27007
@NP	group	27007
@NP	Figure 4 -LRB- B -RRB- , -LRB- e2 -RRB- × 100	27014
@NP	Figure	27014
@NP	4 -LRB- B -RRB- , -LRB- e2 -RRB- × 100	27021
@NP	4 -LRB- B -RRB- , -LRB- e2 -RRB-	27021
@NP	4 -LRB- B -RRB-	27021
@NP	4	27021
@NP	B	27023
@NP	e2	27028
@NP	× 100	27032
@NP	3.5	27039
@NP	Cellular Apoptosis after Spinal Cord Injury	27044
@NP	Cellular Apoptosis	27044
@NP	Spinal Cord Injury	27069
@NP	Olfactory Ensheathing Cells with Bone Marrow Mesenchymal Stem Cells	27103
@NP	Olfactory Ensheathing Cells	27103
@NP	Bone Marrow Mesenchymal Stem Cells	27136
@NP	We	27172
@NP	the TUNEL method	27180
@NP	the occurrence of apoptosis	27208
@NP	the occurrence	27208
@NP	apoptosis	27226
@NP	the spinal cord	27239
@NP	SCI -LRB- Figure 5 -RRB-	27261
@NP	SCI	27261
@NP	Figure 5	27266
@NP	14 and 28 days after transplantation , TUNEL staining results of each group	27277
@NP	14 and 28 days	27277
@NP	transplantation , TUNEL staining results of each group	27298
@NP	transplantation	27298
@NP	TUNEL staining results of each group	27315
@NP	TUNEL staining results	27315
@NP	each group	27341
@NP	TUNEL-positive cells	27365
@NP	white matter	27414
@NP	rats 14 and 28 days	27430
@NP	rats	27430
@NP	14 and 28 days	27435
@NP	transplantation	27456
@NP	comparison	27477
@NP	the spinal cord cell apoptosis rate showedmuch difference	27491
@NP	control group rats	27555
@NP	those in the sham groups and OECs	27578
@NP	those	27578
@NP	the sham groups and OECs	27587
@NP	BMSCs	27621
@NP	cotransplant treated groups	27640
@NP	14 and 28 days after transplantation -LRB- Figure 5 -LRB- C -RRB- -RRB-	27668
@NP	14 and 28 days	27668
@NP	transplantation -LRB- Figure 5 -LRB- C -RRB- -RRB-	27689
@NP	transplantation	27689
@NP	Figure 5 -LRB- C -RRB-	27706
@NP	Figure	27706
@NP	5 -LRB- C -RRB-	27713
@NP	The higher spinal cord cell apoptosis rate in the sham group and OECs treated	27720
@NP	The higher spinal cord cell apoptosis rate in the sham group	27720
@NP	The higher spinal cord cell apoptosis rate	27720
@NP	the sham group	27766
@NP	OECs treated	27785
@NP	OECs	27785
@NP	BMSCs treated	27799
@NP	BMSCs	27799
@NP	cotransplant treated groups	27818
@NP	the control group	27873
@NP	14 days	27891
@NP	transplantation -LRB- < 0.05 -RRB-	27905
@NP	transplantation	27905
@NP	< 0.05	27925
@NP	<	27925
@NP	0.05	27927
@NP	Figures 5 -LRB- A -RRB- and 5 -LRB- C -RRB-	27934
@NP	Figures	27934
@NP	5 -LRB- A -RRB- and 5 -LRB- C -RRB-	27942
@NP	5 -LRB- A -RRB-	27942
@NP	5 -LRB- C -RRB-	27951
@NP	The spinal cord cell apoptosis rate in the OECs treated	27958
@NP	The spinal cord cell apoptosis rate	27958
@NP	the OECs treated	27997
@NP	the OECs	27997
@NP	BMSCs treated	28015
@NP	BMSCs	28015
@NP	cotransplant treated groups	28034
@NP	that	28100
@NP	the sham groups -LRB- < 0.05 -RRB-	28108
@NP	the sham groups	28108
@NP	< 0.05	28128
@NP	<	28128
@NP	0.05	28130
@NP	Figures 5 -LRB- A -RRB- and 5 -LRB- C -RRB-	28137
@NP	Figures	28137
@NP	5 -LRB- A -RRB- and 5 -LRB- C -RRB-	28145
@NP	5 -LRB- A -RRB-	28145
@NP	5 -LRB- C -RRB-	28154
@NP	We	28161
@NP	the spinal cord cell apoptosis rate in cotransplant treated group	28180
@NP	the spinal cord cell apoptosis rate	28180
@NP	cotransplant treated group	28219
@NP	that in the OECs treated	28261
@NP	that	28261
@NP	the OECs treated	28269
@NP	the OECs	28269
@NP	BMSCs	28290
@NP	groups	28304
@NP	28 days	28311
@NP	transplantation	28325
@NP	< 0.05	28345
@NP	<	28345
@NP	0.05	28347
@NP	Figures 5 -LRB- B -RRB- and 5 -LRB- C -RRB-	28354
@NP	Figures	28354
@NP	5 -LRB- B -RRB- and 5 -LRB- C -RRB-	28362
@NP	5 -LRB- B -RRB-	28362
@NP	5 -LRB- C -RRB-	28371
@NP	The spinal cord cell apoptosis rate in the shamgroups , theOECs treated group	28378
@NP	The spinal cord cell apoptosis rate	28378
@NP	the shamgroups , theOECs treated group	28417
@NP	the shamgroups	28417
@NP	theOECs treated group	28433
@NP	theOECs	28433
@NP	group	28449
@NP	BMSCs treated group	28456
@NP	BMSCs	28456
@NP	group	28470
@NP	cotransplant treated group	28481
@NP	the higher spinal cord cell apoptosis rate	28526
@NP	the higher spinal cord cell	28526
@NP	apoptosis rate	28554
@NP	sham groups	28585
@NP	the control group	28611
@NP	the OECs treated group	28630
@NP	the OECs	28630
@NP	group	28647
@NP	BMSCs treated group	28654
@NP	BMSCs	28654
@NP	group	28668
@NP	cotransplant treated group	28679
@NP	28 days	28706
@NP	transplantation -LRB- < 0.05 -RRB-	28720
@NP	transplantation	28720
@NP	< 0.05	28740
@NP	<	28740
@NP	0.05	28742
@NP	Figures 5 -LRB- B -RRB- and 5 -LRB- C -RRB-	28749
@NP	Figures	28749
@NP	5 -LRB- B -RRB- and 5 -LRB- C -RRB-	28757
@NP	5 -LRB- B -RRB-	28757
@NP	5 -LRB- C -RRB-	28766
@NP	these results	28782
@NP	we	28797
@NP	the cotransplantation of OECs with BMSCs	28819
@NP	the cotransplantation	28819
@NP	OECs with BMSCs	28844
@NP	OECs	28844
@NP	BMSCs	28854
@NP	antiapoptotic effects in adult rats	28867
@NP	antiapoptotic effects	28867
@NP	adult rats	28892
@NP	SCI	28909
@NP	3.6	28914
@NP	Expressions of Bax , Bcl-2 , Caspase-9 , and Caspase-3 in Spinal Cord of Rats	28919
@NP	Expressions	28919
@NP	Bax , Bcl-2 , Caspase-9 , and Caspase-3 in Spinal Cord of Rats	28934
@NP	Bax , Bcl-2 , Caspase-9 , and Caspase-3	28934
@NP	Spinal Cord of Rats	28974
@NP	Spinal Cord	28974
@NP	Rats	28989
@NP	Olfactory Ensheathing Cells with Bone Marrow	29012
@NP	Olfactory Ensheathing Cells	29012
@NP	Bone Marrow	29045
@NP	Mesenchymal Stem Cells 14	29057
@NP	Mesenchymal Stem Cells	29057
@NP	14	29080
@NP	28 Days after Transplantation	29087
@NP	28 Days	29087
@NP	Transplantation	29101
@NP	The expressions of Caspase-9 and Caspase-3	29595
@NP	The expressions	29595
@NP	Caspase-9 and Caspase-3	29614
@NP	cotransplant	29651
@NP	treated groups	29664
@NP	those	29709
@NP	OECs	29718
@NP	groups and BMSCs	29731
@NP	groups	29756
@NP	28 days	29763
@NP	transplantation	29777
@NP	< 0.05	29797
@NP	<	29797
@NP	0.05	29799
@NP	Figures 6 -LRB- d -RRB- and 6 -LRB- e -RRB-	29806
@NP	Figures	29806
@NP	6 -LRB- d -RRB- and 6 -LRB- e -RRB-	29814
@NP	6 -LRB- d -RRB-	29814
@NP	6 -LRB- e -RRB-	29823
@NP	Caspase-9 and Caspase-3	29841
@NP	cotransplant treated groups	29878
@NP	no significant difference	29912
@NP	control groups	29957
@NP	28 days	29972
@NP	transplantation	29986
@NP	> 0.05	30006
@NP	>	30006
@NP	0.05	30008
@NP	Figures 6 -LRB- d -RRB- and 6 -LRB- e -RRB-	30015
@NP	Figures	30015
@NP	6 -LRB- d -RRB- and 6 -LRB- e -RRB-	30023
@NP	6 -LRB- d -RRB-	30023
@NP	6 -LRB- e -RRB-	30032
@NP	There	30039
@NP	higher expression of Bcl-2 protein in cotransplant treated groups	30049
@NP	higher expression	30049
@NP	Bcl-2 protein in cotransplant treated groups	30070
@NP	Bcl-2 protein	30070
@NP	cotransplant treated groups	30087
@NP	28 days	30115
@NP	transplantation -LRB- < 0.05 -RRB-	30129
@NP	transplantation	30129
@NP	< 0.05	30149
@NP	<	30149
@NP	0.05	30151
@NP	c	30167
@NP	Bax	30180
@NP	little change in each group -LRB- Figure 6 -LRB- b -RRB- -RRB-	30188
@NP	little change	30188
@NP	each group -LRB- Figure 6 -LRB- b -RRB- -RRB-	30205
@NP	each group	30205
@NP	Figure 6 -LRB- b -RRB-	30217
@NP	Figure	30217
@NP	6 -LRB- b -RRB-	30224
@NP	3.7	30231
@NP	Recovery	30236
@NP	Locomotor Function	30248
@NP	Rats Cotransplanted with Olfactory Ensheathing Cells	30270
@NP	Rats Cotransplanted	30270
@NP	Olfactory Ensheathing Cells	30295
@NP	Bone Marrow Mesenchymal Stem Cells	30328
@NP	we	30373
@NP	inhibition of apoptotic by OECs and MSCs	30391
@NP	inhibition	30391
@NP	apoptotic by OECs and MSCs	30405
@NP	apoptotic	30405
@NP	OECs and MSCs	30418
@NP	the functional recovery of rats	30455
@NP	the functional recovery	30455
@NP	rats	30482
@NP	BBB scores	30488
@NP	all time points	30502
@NP	transplantation for the cotransplant treated	30524
@NP	transplantation	30524
@NP	the cotransplant treated	30544
@NP	the cotransplant	30544
@NP	OECs treated	30570
@NP	OECs	30570
@NP	BMSCs treated groups and control groups	30588
@NP	BMSCs	30588
@NP	groups and control groups	30602
@NP	Tables 2 and 3	30641
@NP	the mean BBB score	30675
@NP	the treatment groups	30721
@NP	that in control groups before transplantation -LRB- < 0.05 -RRB-	30754
@NP	that	30754
@NP	control groups before transplantation -LRB- < 0.05 -RRB-	30762
@NP	control groups	30762
@NP	transplantation -LRB- < 0.05 -RRB-	30784
@NP	transplantation	30784
@NP	< 0.05	30804
@NP	<	30804
@NP	0.05	30806
@NP	Recovery of function	30813
@NP	Recovery	30813
@NP	function	30825
@NP	the course	30868
@NP	the 14-day observation period in the OECs treated group	30882
@NP	the 14-day observation period	30882
@NP	the OECs treated group	30915
@NP	the OECs	30915
@NP	group	30932
@NP	BMSCs treated group	30939
@NP	BMSCs	30939
@NP	group	30953
@NP	cotransplant treated group	30964
@NP	Rats in the transplanted groups	30992
@NP	Rats	30992
@NP	the transplanted groups	31000
@NP	a significant improvement in the BBB scale	31031
@NP	a significant improvement	31031
@NP	the BBB scale	31060
@NP	the sham	31086
@NP	control group 14 , 21 , and 28 days	31103
@NP	control group 14 , 21 , and 28	31103
@NP	control group	31103
@NP	14 , 21 , and 28	31117
@NP	transplantation -LRB- < 0.05 -RRB- -LRB- Table 3 -RRB-	31143
@NP	transplantation -LRB- < 0.05 -RRB-	31143
@NP	transplantation	31143
@NP	< 0.05	31163
@NP	<	31163
@NP	0.05	31165
@NP	Table 3	31172
@NP	The BBB scale in cotransplant treated group	31182
@NP	The BBB scale	31182
@NP	cotransplant treated group	31199
@NP	that	31262
@NP	OECs	31270
@NP	group and BMSCs	31283
@NP	group 21 and 28 days	31307
@NP	group 21	31307
@NP	28 days	31320
@NP	transplantation -LRB- < 0.05 -RRB- -LRB- Table 3 -RRB-	31334
@NP	transplantation -LRB- < 0.05 -RRB-	31334
@NP	transplantation	31334
@NP	< 0.05	31354
@NP	<	31354
@NP	0.05	31356
@NP	Table 3	31363
@NP	Discussion Transplantation of OECs and BMSCs	31377
@NP	Discussion Transplantation	31377
@NP	OECs and BMSCs	31407
@NP	therapy of SCI -LSB- 27 -- 30	31482
@NP	therapy	31482
@NP	SCI -LSB- 27 -- 30	31493
@NP	clinical application	31516
@NP	the margin neuronal differentiation capacity of BMSC	31559
@NP	the margin neuronal differentiation capacity	31559
@NP	BMSC	31607
@NP	the limited number of isolatableOECs	31623
@NP	the limited number	31623
@NP	isolatableOECs	31645
@NP	advantage	31669
@NP	the limitations	31691
@NP	ofOECs and BMSCs	31707
@NP	the cotransplantation of the two major types of cells	31725
@NP	the cotransplantation	31725
@NP	the two major types of cells	31750
@NP	the two major types	31750
@NP	cells	31773
@NP	therapeutic for SCI	31801
@NP	therapeutic	31801
@NP	SCI	31817
@NP	this study	31825
@NP	we successfully coculture the two types of cells in vitro	31837
@NP	we successfully coculture the two types	31837
@NP	we	31837
@NP	coculture the two types	31853
@NP	coculture	31853
@NP	the two types	31863
@NP	cells in vitro	31880
@NP	cells	31880
@NP	There	31896
@NP	no morphological change in cell.We	31906
@NP	no morphological change	31906
@NP	cell.We	31933
@NP	the cells immunofluorescence	31950
@NP	the viability of the individual	31992
@NP	the viability	31992
@NP	the individual	32009
@NP	cells	32039
@NP	BMSCs	32046
@NP	rapid proliferation	32059
@NP	more pronounced increase	32084
@NP	the number of cells	32112
@NP	the number	32112
@NP	cells	32126
@NP	the OECs	32139
@NP	low growth rate	32153
@NP	nonsignificant increase in cell number during the culture period.There	32175
@NP	nonsignificant increase	32175
@NP	cell number during the culture period.There	32202
@NP	cell number	32202
@NP	the culture period.There	32221
@NP	the number of each cell	32271
@NP	the number	32271
@NP	each cell	32285
@NP	the imbalance	32304
@NP	the proportion of cells in the coculture system	32321
@NP	the proportion	32321
@NP	cells in the coculture system	32339
@NP	cells	32339
@NP	the coculture system	32348
@NP	Consistent with several previous studies -LSB- 31	32370
@NP	Consistent	32370
@NP	several previous studies -LSB- 31	32386
@NP	several previous studies	32386
@NP	31	32412
@NP	33 -RSB-	32415
@NP	this study	32423
@NP	we	32434
@NP	transplantation of either of OECs or BMSCs	32455
@NP	transplantation	32455
@NP	either of OECs or BMSCs	32474
@NP	either	32474
@NP	OECs or BMSCs	32484
@NP	functional recovery of rats	32523
@NP	functional recovery	32523
@NP	rats	32546
@NP	SCI	32557
@NP	the cotransplantation of OECs and BMSCs	32577
@NP	the cotransplantation	32577
@NP	OECs and BMSCs	32602
@NP	the most effective in comparison with that of OECs or BMSCs	32638
@NP	the most effective	32638
@NP	comparison with that of OECs or BMSCs	32660
@NP	comparison	32660
@NP	that of OECs or BMSCs	32676
@NP	that	32676
@NP	OECs or BMSCs	32684
@NP	the two cell typesmay	32725
@NP	a synergistic way	32759
@NP	the functional recovery of SCI	32788
@NP	the functional recovery	32788
@NP	SCI	32815
@NP	Deng et al. -LSB- 34 -RSB-	32820
@NP	Deng et al. -LSB-	32820
@NP	the cotransplant group	32855
@NP	significantly better improvement of gait scaling compared with all other groups	32896
@NP	significantly better improvement	32896
@NP	gait scaling compared with all other groups	32932
@NP	gait scaling	32932
@NP	all other groups	32959
@NP	2 weeks of transplantation.TheBMSC group	32982
@NP	2 weeks	32982
@NP	transplantation.TheBMSC group	32993
@NP	higher BBB scores	33041
@NP	the OEC group , which is consistent with our findings	33064
@NP	the OEC group	33064
@NP	our findings	33104
@NP	the cotransplant of OECs and BMSCs	33131
@NP	the cotransplant	33131
@NP	OECs and BMSCs	33151
@NP	effective change	33178
@NP	that of OECs and BMSCs	33209
@NP	that	33209
@NP	OECs and BMSCs	33217
@NP	this regard	33242
@NP	the cograft of mixed cell types with complementary properties	33255
@NP	the cograft	33255
@NP	mixed cell types with complementary properties	33270
@NP	mixed cell types	33270
@NP	complementary properties	33292
@NP	a novel approach for cell transplantation	33329
@NP	a novel approach	33329
@NP	cell transplantation	33350
@NP	SCI and even other tissue types	33374
@NP	SCI	33374
@NP	other tissue types	33387
@NP	much attention	33416
@NP	secondary cord injury	33448
@NP	this	33476
@NP	therapeutic intervention	33511
@NP	Apoptosis and inflammatory responses and some other neurological toxicity events	33537
@NP	Apoptosis and inflammatory responses	33537
@NP	some other neurological toxicity events	33578
@NP	the secondary injury	33630
@NP	primary insult inthe spinal cord -LSB- 1 , 35 -RSB-	33657
@NP	primary insult inthe	33657
@NP	-LSB- 1 , 35	33690
@NP	this study	33710
@NP	the possible synergistic effects of the two cells	33739
@NP	the possible synergistic effects	33739
@NP	the two cells	33775
@NP	antiapoptotic effects	33793
@NP	cotransplantation in rat SCI models	33821
@NP	cotransplantation	33821
@NP	rat SCI models	33842
@NP	We	33858
@NP	decreased apoptosis in rats	33867
@NP	decreased apoptosis	33867
@NP	rats	33890
@NP	group of cotransplantation of OECs and BMSCs	33900
@NP	group	33900
@NP	cotransplantation of OECs and BMSCs	33909
@NP	cotransplantation	33909
@NP	OECs and BMSCs	33930
@NP	apoptosis study using TUNEL assay which showed	33950
@NP	apoptosis study	33950
@NP	TUNEL assay which showed	33972
@NP	TUNEL assay	33972
@NP	The spinal cord cell apoptosis rate in the OECs treated	33998
@NP	The spinal cord cell apoptosis rate	33998
@NP	the OECs treated	34037
@NP	the OECs	34037
@NP	BMSCs treated	34055
@NP	BMSCs	34055
@NP	cotransplant treated groups	34074
@NP	that in the sham groups	34140
@NP	that	34140
@NP	the sham groups	34148
@NP	the spinal cord cell apoptosis rate in cotransplant treated group	34178
@NP	the spinal cord cell apoptosis rate	34178
@NP	cotransplant treated group	34217
@NP	that in the OECs treated and BMSCs treated groups 28 days after transplantation	34259
@NP	that in the OECs treated	34259
@NP	that	34259
@NP	the OECs treated	34267
@NP	the OECs	34267
@NP	BMSCs treated groups 28 days after transplantation	34288
@NP	BMSCs	34288
@NP	groups	34302
@NP	28 days	34309
@NP	transplantation	34323
@NP	we	34355
@NP	death of injured spinal cord cells in whitematter following spinal cord injury	34374
@NP	death	34374
@NP	injured spinal cord cells in whitematter following spinal cord injury	34383
@NP	injured spinal cord cells	34383
@NP	whitematter following spinal cord injury	34412
@NP	whitematter	34412
@NP	spinal cord injury	34434
@NP	the regulations processing of Bax , Bcl-2 , Caspase-9 , andCaspase - 3	34462
@NP	the regulations processing of Bax , Bcl-2 , Caspase-9 , andCaspase	34462
@NP	the regulations processing	34462
@NP	Bax , Bcl-2 , Caspase-9 , andCaspase	34492
@NP	3	34527
@NP	the apoptotic death of cells in the spinal cord	34560
@NP	the apoptotic death	34560
@NP	cells in the spinal cord	34583
@NP	cells	34583
@NP	the spinal cord	34592
@NP	Increased activity of theCaspase family of proteases	34609
@NP	Increased activity	34609
@NP	theCaspase family of proteases	34631
@NP	theCaspase family	34631
@NP	proteases	34652
@NP	apoptosis	34681
@NP	Caspase	34704
@NP	3	34713
@NP	a crucial role	34721
@NP	SCI-mediated apoptotic cell death in the white matter -LSB- 14 , 36	34739
@NP	SCI-mediated apoptotic cell death	34739
@NP	the white matter	34776
@NP	-LSB- 14 , 36	34793
@NP	mechanisms underlying suppression	34818
@NP	apoptosis	34855
@NP	cotransplantation of OECs and BMSCs	34871
@NP	cotransplantation	34871
@NP	OECs and BMSCs	34892
@NP	SCI	34913
@NP	we	34918
@NP	the Bax , Bcl-2 , Caspase-9 , and Caspase - 3 expression in apoptosis	34935
@NP	the Bax , Bcl-2 , Caspase-9 , and Caspase	34935
@NP	3 expression in apoptosis	34975
@NP	3 expression	34975
@NP	apoptosis	34991
@NP	Western blot	35004
@NP	The results	35018
@NP	the expression of Caspase-9 and Caspase - 3 and the ratio of Bax/Bcl -2	35048
@NP	the expression of Caspase-9 and Caspase - 3 and the ratio	35048
@NP	the expression of Caspase-9 and Caspase	35048
@NP	the expression	35048
@NP	Caspase-9 and Caspase	35066
@NP	3 and the ratio	35089
@NP	3	35089
@NP	the ratio	35095
@NP	Bax/Bcl -2	35108
@NP	the cotransplant treated group compared with those in the sham groups	35150
@NP	the cotransplant	35150
@NP	group	35175
@NP	those in the sham groups	35195
@NP	those	35195
@NP	the sham groups	35204
@NP	the expression of Bax	35230
@NP	the expression	35230
@NP	Bax	35248
@NP	little change in each group	35256
@NP	little change	35256
@NP	each group	35273
@NP	we	35296
@NP	downregulation of Bcl-2 and consequently the higher ratio of Bax/Bcl -2	35315
@NP	downregulation of Bcl-2	35315
@NP	downregulation	35315
@NP	Bcl-2	35333
@NP	the higher ratio of Bax/Bcl -2	35356
@NP	the higher ratio	35356
@NP	Bax/Bcl -2	35376
@NP	the release of Caspase-9 and Caspase-3	35418
@NP	the release	35418
@NP	Caspase-9 and Caspase-3	35433
@NP	the latter	35467
@NP	apoptosis	35498
@NP	SCI	35514
@NP	The cotransplantation of OECs with BMSCs	35519
@NP	The cotransplantation	35519
@NP	OECs with BMSCs	35544
@NP	OECs	35544
@NP	BMSCs	35554
@NP	antiapoptotic effects in adult rats	35567
@NP	antiapoptotic effects	35567
@NP	adult rats	35592
@NP	spinal cord injury by inhibiting downregulation of Bcl-2 expression	35609
@NP	spinal cord injury	35609
@NP	inhibiting downregulation of Bcl-2 expression	35631
@NP	inhibiting downregulation	35631
@NP	Bcl-2 expression	35660
@NP	the decrease	35692
@NP	the ratio	35708
@NP	Bax/Bcl -2 results	35721
@NP	the suppression of Caspase-9 and Caspase-3	35742
@NP	the suppression	35742
@NP	Caspase-9 and Caspase-3	35761
@NP	a decrease in the number of apoptotic cells	35797
@NP	a decrease	35797
@NP	the number of apoptotic cells	35811
@NP	the number	35811
@NP	apoptotic cells	35825
@NP	the cotransplant	35844
@NP	group	35869
@NP	These findings	35876
@NP	OECs and BMSCs	35914
@NP	the neuroprotective effects	35944
@NP	apoptotic processes	35985
@NP	the expression of the mitochondria-associated intrinsic pathway related proteins	36019
@NP	the expression	36019
@NP	the mitochondria-associated intrinsic pathway related proteins	36037
@NP	secondary damage of SCI	36107
@NP	secondary damage	36107
@NP	SCI	36127
@NP	this study	36135
@NP	we	36147
@NP	transplantation of OECs , BMSCs , and cotransplantation of OECs with BMSCs	36161
@NP	transplantation	36161
@NP	OECs , BMSCs , and cotransplantation	36180
@NP	OECs with BMSCs	36218
@NP	OECs	36218
@NP	BMSCs	36228
@NP	functional activities of rats	36260
@NP	functional activities	36260
@NP	rats	36285
@NP	two weeks of transplantation	36296
@NP	two weeks	36296
@NP	transplantation	36309
@NP	we	36339
@NP	there	36353
@NP	significant functional recovery	36363
@NP	improvement in the number of intact axons across the injury site	36396
@NP	improvement	36396
@NP	the number of intact axons across the injury site	36411
@NP	the number	36411
@NP	intact axons across the injury site	36425
@NP	intact axons	36425
@NP	the injury site	36445
@NP	a decrease	36466
@NP	white matter loss	36480
@NP	cotransplant treated group	36501
@NP	that	36540
@NP	OECs treated group and BMSCs treated group 21 and 28 days after transplantation	36548
@NP	OECs	36548
@NP	group and BMSCs treated group 21 and 28 days after transplantation	36561
@NP	group and BMSCs	36561
@NP	group 21 and 28 days	36585
@NP	group 21	36585
@NP	28 days	36598
@NP	transplantation	36612
@NP	The finding of the locomotor recovery in treated rats	36629
@NP	The finding	36629
@NP	the locomotor recovery in treated rats	36644
@NP	the locomotor recovery	36644
@NP	treated rats	36670
@NP	the mitochondriaassociated intrinsic pathway	36697
@NP	a potential therapeutic target in the treatment of SCI	36751
@NP	a potential therapeutic target	36751
@NP	the treatment of SCI	36785
@NP	the treatment	36785
@NP	SCI	36802
@NP	Our study	36807
@NP	the previous studies	36835
@NP	37 -- 41	36857
@NP	stem cells	36880
@NP	the injured areas	36923
@NP	neural cells	36961
@NP	the functional recovery of these animals	36987
@NP	the functional recovery	36987
@NP	these animals	37014
@VP	have not been fully understood.Therefore	402
@VP	been fully understood.Therefore	411
@VP	are induced	583
@VP	induced	587
@VP	assessed animal locomotion using BBB test	781
@VP	using BBB test	808
@VP	had a remissive effect on behavioral outcome	868
@VP	induced SCI	943
@VP	observed the significant antiapoptotic effect on cotransplant treated group	972
@VP	found to have more significant repairing effect than that of OECs or BMSCs alone	1103
@VP	to have more significant repairing effect than that of OECs or BMSCs alone	1109
@VP	have more significant repairing effect than that of OECs or BMSCs alone	1112
@VP	repairing effect than that of OECs or BMSCs alone	1134
@VP	downregulating the apoptotic pathways	1291
@VP	to incorporate into the spinal cord	1464
@VP	incorporate into the spinal cord	1467
@VP	1	1502
@VP	may replace endogenous destroyed cells through facilitating cell regeneration	1871
@VP	replace endogenous destroyed cells through facilitating cell regeneration	1875
@VP	destroyed cells through facilitating cell regeneration	1894
@VP	facilitating cell regeneration	1918
@VP	differentiate into neurons -LSB- 1 -RSB-	1953
@VP	using different types of cells in preclinical models -LSB- 2 , 3 -RSB-	2042
@VP	studied cells for SCI repair in experimental models	2213
@VP	showed good perspectives for clinical applications of cell therapy	2269
@VP	enhance outgrowth of both intact and lesioned axons , activate angiogenesis	2620
@VP	reduce the volume of injured tissue	2999
@VP	promote axonal regeneration	3036
@VP	recover some functions -LSB- 7 -RSB-	3069
@VP	have been proposed as one of the most promising cell sources for SCI therapy	3367
@VP	been proposed as one of the most promising cell sources for SCI therapy	3372
@VP	proposed as one of the most promising cell sources for SCI therapy	3377
@VP	underlying the beneficial effects of BMSCs transplants	3585
@VP	appears to be susceptible for therapeutic intervention	4049
@VP	to be susceptible for therapeutic intervention	4057
@VP	be susceptible for therapeutic intervention	4060
@VP	are activated in spinal cord injuries -LSB- 14 -RSB-	4385
@VP	activated in spinal cord injuries -LSB- 14 -RSB-	4389
@VP	occur in a temporally similar fashion after SCI -LSB- 18 -RSB-	4580
@VP	using Bcl-2 overexpressed transgenic mice	4759
@VP	overexpressed transgenic mice	4771
@VP	inhibited neuronal apoptosis after spinal cord injury	4844
@VP	improved recovery of neurological function -LSB- 19 -RSB-	4902
@VP	can induce apoptosis	5013
@VP	induce apoptosis	5017
@VP	quickly translocates tomitochondria at an early stage of the apoptotic process	5038
@VP	to recover from injury	5381
@VP	recover from injury	5384
@VP	is limited	5404
@VP	to replace the damaged neurons and oligodendrocytes	5499
@VP	replace the damaged neurons and oligodendrocytes	5502
@VP	enhance neuronal plasticity	5555
@VP	migrate	5858
@VP	differentiate into myocardiocytes and neurons	5923
@VP	may have stronger effects on neural degeneration induced by SCI	6058
@VP	have stronger effects on neural degeneration induced by SCI	6062
@VP	induced by SCI	6107
@VP	may be mediated throughthe regulationofBax,Bcl-2 , Caspase-9 , andCaspase-3	6228
@VP	be mediated throughthe regulationofBax,Bcl-2 , Caspase-9 , andCaspase-3	6232
@VP	mediated throughthe regulationofBax,Bcl-2 , Caspase-9 , andCaspase-3	6235
@VP	To test the hypothesis	6301
@VP	test the hypothesis	6304
@VP	evaluated behavioral activities and histopathological changes	6418
@VP	involved in mitochondria-associated apoptotic pathway	6523
@VP	2	6579
@VP	is SCXK -LRB- Lu -RRB- 2013-0009	6826
@VP	were provided ad libitum	6998
@VP	provided ad libitum	7003
@VP	were evaluated with different parameters as shown in Figure 1	7929
@VP	evaluated with different parameters as shown in Figure 1	7934
@VP	shown in Figure 1	7973
@VP	placed prone on an operating table covered with a warming blanket	8205
@VP	covered with a warming blanket	8240
@VP	shaving the midthoracic region and prepping with Betadine	8278
@VP	shaving the midthoracic region	8278
@VP	prepping with Betadine	8313
@VP	was made over the midthoracic region	8349
@VP	made over the midthoracic region	8353
@VP	was performed at the T9 -- T11 under chloral hydrate anesthesia	8411
@VP	performed at the T9 -- T11 under chloral hydrate anesthesia	8415
@VP	was centered above T10	8512
@VP	centered above T10	8516
@VP	dropped from a height of 50mmto induce a consistent partial SCI	8539
@VP	induce a consistent partial SCI	8571
@VP	was achieved using buprenorphine -LRB- 0.1 mg/kg -RRB- for 2 days after surgery	8614
@VP	achieved using buprenorphine -LRB- 0.1 mg/kg -RRB- for 2 days after surgery	8618
@VP	using buprenorphine -LRB- 0.1 mg/kg -RRB- for 2 days after surgery	8627
@VP	to avoid dehydration	8735
@VP	avoid dehydration	8738
@VP	were administrated to prevent urinary tract infection for 3 -- 7 days	8781
@VP	administrated to prevent urinary tract infection for 3 -- 7 days	8786
@VP	to prevent urinary tract infection for 3 -- 7 days	8800
@VP	prevent urinary tract infection for 3 -- 7 days	8803
@VP	was undertaken every day for a week after surgery	8902
@VP	undertaken every day for a week after surgery	8906
@VP	emptying	9042
@VP	was established	9051
@VP	established	9055
@VP	were cultured as	9214
@VP	cultured as	9219
@VP	reported previously with slight modifications -LSB- 23 , 24 -RSB-	9231
@VP	sacrificed by 3 % pentobarbital sodiumanesthetic overdose	9325
@VP	being put in 0.5 % iodophor solution for about 5 minutes	9388
@VP	put in 0.5 % iodophor solution for about 5 minutes	9394
@VP	were dissected in the super-clean bench	9450
@VP	dissected in the super-clean bench	9455
@VP	was cut along the cranial sagittal suture from the foramen magnum	9510
@VP	cut along the cranial sagittal suture from the foramen magnum	9514
@VP	collected andwashed 2 times with PBS	9598
@VP	cut to small pieces with sterile ophthalmic scissors	9639
@VP	being washed with DMEM and centrifuged as above	10054
@VP	washed with DMEM and centrifuged as above	10060
@VP	washed with DMEM	10060
@VP	centrifuged as above	10081
@VP	being blocked with 5 % BSA for 30 minutes	10304
@VP	blocked with 5 % BSA for 30 minutes	10310
@VP	described by Qian et al. -LSB- 25 -RSB-	10706
@VP	was isolated in sterile conditions from 8	10749
@VP	isolated in sterile conditions from 8	10753
@VP	being sacrificed by anesthetic overdose	10881
@VP	sacrificed by anesthetic overdose	10887
@VP	were dissected to get tibia and femur	10927
@VP	dissected to get tibia and femur	10932
@VP	to get tibia and femur	10942
@VP	get tibia and femur	10945
@VP	were observed daily under inverted microscope -LRB- OLYMPUS , Japan -RRB-	11161
@VP	observed daily under inverted microscope -LRB- OLYMPUS , Japan -RRB-	11166
@VP	was added into the culture flasks after incubation for 48	11277
@VP	added into the culture flasks after incubation for 48	11281
@VP	were fixed with 4 % paraformaldehyde for about 20 minutes	11355
@VP	fixed with 4 % paraformaldehyde for about 20 minutes	11360
@VP	digested with 2 % HCl and the pepsin for 10 minutes	11470
@VP	covered with 90 % glycerol	11683
@VP	observed under fluorescence microscope -LRB- OLYMPUS , Japan -RRB-	11713
@VP	were purified and were mixed together into single cell suspension	11810
@VP	were purified	11810
@VP	purified	11815
@VP	were mixed together into single cell suspension	11828
@VP	mixed together into single cell suspension	11833
@VP	was adjusted to 104/mL	11895
@VP	adjusted to 104/mL	11899
@VP	were placed in CO2 incubator	11930
@VP	placed in CO2 incubator	11935
@VP	was replaced every 3 to 4 days	11967
@VP	replaced every 3 to 4 days	11971
@VP	were covered more than 60 % to start identification , and repeated above steps	12011
@VP	covered more than 60 % to start identification , and repeated above steps	12016
@VP	covered more than 60 % to start identification	12016
@VP	to start identification	12038
@VP	start identification	12041
@VP	repeated above steps	12067
@VP	was measured using WST-8 cell counting kit -LRB- CCK-8 , DOJINDO , Japan -RRB-	12135
@VP	measured using WST-8 cell counting kit -LRB- CCK-8 , DOJINDO , Japan -RRB-	12139
@VP	using WST-8 cell counting kit -LRB- CCK-8 , DOJINDO , Japan -RRB-	12148
@VP	performed according to the manufacturer 's instruction with slight modifications	12217
@VP	seeded into a well of a 96-well plate at 90 per well	12332
@VP	cultured for different time periods -LRB- 2 , 4 , 6 , 8 , 10 , and 12 days -RRB-	12393
@VP	well followed by incubation for 1 h at 37 ∘ C.	12563
@VP	was detected by a microplate reader -LRB- Thermo Fisher , USA -RRB-	12634
@VP	detected by a microplate reader -LRB- Thermo Fisher , USA -RRB-	12638
@VP	was performed in triplicate and repeated independently three times	12708
@VP	performed in triplicate and repeated independently three times	12712
@VP	performed in triplicate	12712
@VP	repeated independently three times	12740
@VP	was expressed as the growth rate with respect to the cell number of the day	12791
@VP	expressed as the growth rate with respect to the cell number of the day	12795
@VP	Procedure	12889
@VP	were used for transplantation	13434
@VP	used for transplantation	13439
@VP	were operated on 7 days later after SCI	13470
@VP	operated on 7 days later after SCI	13475
@VP	were anesthetized	13524
@VP	was made in the dura at the injection site.Then	13724
@VP	made in the dura at the injection site.Then	13728
@VP	was inserted into the spinal cord at the midline to a depth of 1 to 1.5 mm	13795
@VP	inserted into the spinal cord at the midline to a depth of 1 to 1.5 mm	13799
@VP	was then injected over 2 minutes	13942
@VP	injected over 2 minutes	13951
@VP	to minimize cell leakage	14053
@VP	minimize cell leakage	14056
@VP	were transplanted into the spinal cord in the same manner	14126
@VP	transplanted into the spinal cord in the same manner	14131
@VP	had DMEM culture medium and serum `` transplanted '' in the same way	14383
@VP	`` transplanted '' in the same way	14417
@VP	isolated and excised with a razor blade	14604
@VP	then fixed in 10 % -LRB- v/v -RRB-	14648
@VP	embedded in paraffin blocks	14734
@VP	sectioned into 5 slice and mounted onto the glass slides	14763
@VP	sectioned into 5 slice	14763
@VP	mounted onto the glass slides	14794
@VP	were taken using optical microscope -LRB- Leica DM4000M , Germany -RRB-	14967
@VP	taken using optical microscope -LRB- Leica DM4000M , Germany -RRB-	14972
@VP	using optical microscope -LRB- Leica DM4000M , Germany -RRB-	14978
@VP	were blind to the pathologists	15080
@VP	were peerreviewed by other certified veterinary pathologists	15128
@VP	peerreviewed by other certified veterinary pathologists	15133
@VP	certified veterinary pathologists	15155
@VP	were deeply anesthetized with ketamine/xylazine	15262
@VP	treated	15618
@VP	incubated in 3 % H2O2	15804
@VP	followed by washing with permeabilization solution	15853
@VP	washing with permeabilization solution	15865
@VP	washed twice with PBS , incubated in TUNEL reactionmixture , and rinsed again	15979
@VP	washed twice with PBS	15979
@VP	incubated in TUNEL reactionmixture	16002
@VP	rinsed again	16042
@VP	visualized using converter-PODwith 0.02 % 3,3 - diaminobenzidine -LRB- DAB -RRB-	16066
@VP	using converter-PODwith 0.02 % 3,3 - diaminobenzidine -LRB- DAB -RRB-	16077
@VP	was used for counter-staining	16156
@VP	used for counter-staining	16160
@VP	were finally mounted onto gelatin-coated slides	16200
@VP	mounted onto gelatin-coated slides	16213
@VP	were air-dried overnight at room temperature	16262
@VP	stained nucleus	16315
@VP	was TUNEL-positive cells	16331
@VP	was used	16397
@VP	used	16401
@VP	selected and magnified 10 times for observation under the microscope objective	16460
@VP	were photographed into computer -LRB- resolution is 800 × 600 -RRB-	16642
@VP	photographed into computer -LRB- resolution is 800 × 600 -RRB-	16647
@VP	is 800 × 600	16686
@VP	was employed to calculate intestinal epithelial cell apoptosis index	16753
@VP	employed to calculate intestinal epithelial cell apoptosis index	16757
@VP	to calculate intestinal epithelial cell apoptosis index	16766
@VP	calculate intestinal epithelial cell apoptosis index	16769
@VP	equals the apoptosis rate of this field	16881
@VP	was the apoptosis rate of rat spinal cord cells in the group	16971
@VP	was used to detect protein expression of Bax , Bcl-2 , Caspase-9 , and Caspase-3	17071
@VP	used to detect protein expression of Bax , Bcl-2 , Caspase-9 , and Caspase-3	17075
@VP	to detect protein expression of Bax , Bcl-2 , Caspase-9 , and Caspase-3	17080
@VP	detect protein expression of Bax , Bcl-2 , Caspase-9 , and Caspase-3	17083
@VP	were euthanized	17262
@VP	euthanized	17267
@VP	centered on T10	17310
@VP	were rapidly removed	17326
@VP	weighed , and frozen at −	17348
@VP	weighed	17348
@VP	frozen at −	17361
@VP	followed by centrifuge for 10 min -LRB- 12,000 r/min , at 4 ∘ C -RRB-	17500
@VP	were collected for protein determination	17575
@VP	collected for protein determination	17580
@VP	separated by SDSPAGE	17647
@VP	resolving gels , 5 % stacking gels	17673
@VP	stacking gels	17692
@VP	using an enhanced chemiluminescence detection system	18237
@VP	were exposed to XOmat AR film -LRB- Eastman Kodak Company , USA -RRB-	18333
@VP	exposed to XOmat AR film -LRB- Eastman Kodak Company , USA -RRB-	18338
@VP	to XOmat AR film -LRB- Eastman Kodak Company , USA -RRB-	18346
@VP	XOmat AR film -LRB- Eastman Kodak Company , USA -RRB-	18349
@VP	were performed in triplicate to ensure reproducibility	18512
@VP	performed in triplicate to ensure reproducibility	18517
@VP	to ensure reproducibility	18541
@VP	ensure reproducibility	18544
@VP	described in Basso et al. -LSB- 26 -RSB-	18746
@VP	used for measuring hind limb function with these procedures	18788
@VP	measuring hind limb function with these procedures	18797
@VP	coordinated limb movement	19008
@VP	coordinated joint movement	19035
@VP	recorded by digital video camera at each time point	19099
@VP	analyzed by two blind researchers	19155
@VP	were first gently adapted to the open field for the test	19195
@VP	gently adapted to the open field for the test	19206
@VP	had walked continuously in the open field , two investigators conducted	19265
@VP	walked continuously in the open field , two investigators conducted	19269
@VP	conducted	19326
@VP	`` blinded '' to rat treatment status	19391
@VP	were recorded using digital video	19671
@VP	recorded using digital video	19676
@VP	using digital video	19685
@VP	represented as mean ± SD	19963
@VP	compared with other groups for significance	19992
@VP	to compare the differences between groups	20097
@VP	compare the differences between groups	20100
@VP	were considered statistically significant at < 0.05	20148
@VP	considered statistically significant at < 0.05	20153
@VP	3	20205
@VP	were bipolar andmultipolar , woven into a net -LRB- a -RRB-	20747
@VP	woven into a net -LRB- a -RRB-	20775
@VP	were seen to express p75NTR -LRB- green , b -RRB-	20801
@VP	seen to express p75NTR -LRB- green , b -RRB-	20806
@VP	to express p75NTR -LRB- green , b -RRB-	20811
@VP	express p75NTR -LRB- green , b -RRB-	20814
@VP	were compact	20847
@VP	was like spindle -LRB- c -RRB-	20874
@VP	was found to exist in the cell core -LRB- red , d -RRB-	20901
@VP	found to exist in the cell core -LRB- red , d -RRB-	20905
@VP	to exist in the cell core -LRB- red , d -RRB-	20911
@VP	exist in the cell core -LRB- red , d -RRB-	20914
@VP	was reduced by OECs and BMSCs -LRB- TUNEL staining , 10 × 40 -RRB-	21218
@VP	reduced by OECs and BMSCs -LRB- TUNEL staining , 10 × 40 -RRB-	21222
@VP	Note	21275
@VP	treated group	21440
@VP	treated group ; and d < 0.05	21642
@VP	treated group	21642
@VP	d < 0.05	21661
@VP	treated group	21686
@VP	treated group ; and d < 0.05	22175
@VP	treated group	22175
@VP	d < 0.05	22194
@VP	treated group	22219
@VP	became larger and longer , woven into a net on the fifth day	22349
@VP	woven into a net on the fifth day	22375
@VP	showed the shape of spindle after being cultured	22547
@VP	being cultured	22581
@VP	cultured	22587
@VP	became more compact and longer on the fifth day	22600
@VP	was red -LRB- Figures 2 -LRB- c -RRB- and 2 -LRB- d -RRB- -RRB-	22720
@VP	were complete adherent 24 h later	22802
@VP	was short	22852
@VP	became more compact and showed bipolar triode or multipolar one	22892
@VP	became more compact	22892
@VP	showed bipolar triode or multipolar one	22916
@VP	were small	22979
@VP	was shorter	23005
@VP	were OECs	23077
@VP	were BMSCs without green cell membrane	23115
@VP	were green under fluorescence	23287
@VP	was spindle after being cultured	23422
@VP	being cultured	23440
@VP	cultured	23446
@VP	became more compact and longer on the fifth day	23459
@VP	was typical of the spindle	23518
@VP	was obvious	23571
@VP	was red -LRB- Figures 2 -LRB- c -RRB- and 2 -LRB- d -RRB- -RRB-	23640
@VP	did the morphology observation and identification of coculture cells	23676
@VP	were complete adherent 24 h later	23752
@VP	was short	23802
@VP	became more compact and showed bipolar triode or multipolar model	23832
@VP	became more compact	23832
@VP	showed bipolar triode or multipolar model	23856
@VP	were small	23911
@VP	was shorter	23938
@VP	were OECs	24019
@VP	was not different significantly	24123
@VP	showed similar growth rate	24246
@VP	was found in the first two days	24304
@VP	found in the first two days	24308
@VP	maintained the similar level as shown in Figure 1	24389
@VP	shown in Figure 1	24421
@VP	was not entirely consistent -LRB- Figure 3 -RRB-	24520
@VP	were recovered 2 -- 4 hours after surgery	24628
@VP	recovered 2 -- 4 hours after surgery	24633
@VP	were able to drink and eat 6 hours after surgery	24671
@VP	to drink and eat 6 hours	24681
@VP	drink and eat 6 hours	24684
@VP	returned to normal after three day postsurgery	24736
@VP	increased during the observation period	24843
@VP	treated group	24936
@VP	treated group	24957
@VP	decreased until 14 days after surgery -LRB- Table 1 -RRB-	25003
@VP	treated group	25085
@VP	treated group	25106
@VP	increased	25162
@VP	treated group	25237
@VP	treated group	25258
@VP	had not yet reached the presurgery level until the end of the observation period	25554
@VP	reached the presurgery level until the end of the observation period	25566
@VP	was found in the control groups	25735
@VP	found in the control groups	25739
@VP	had integrity boundaries	25791
@VP	was severely damaged	26173
@VP	severely damaged	26177
@VP	induced by spinal cord injury in these three groups	26584
@VP	was less than that in the sham group 14 days after transplantation	26636
@VP	was a decrease in the number of the cavities	26803
@VP	treated group -LRB- Figure 4 -LRB- B -RRB- , -LRB- e2 -RRB- × 100 -RRB-	26999
@VP	Reduced by Olfactory Ensheathing Cells with Bone Marrow Mesenchymal Stem Cells	27092
@VP	can be seen	27352
@VP	be seen	27356
@VP	seen	27359
@VP	observed to distribute white matter in rats 14 and 28 days after transplantation	27391
@VP	to distribute white matter in rats 14 and 28 days after transplantation	27400
@VP	distribute white matter in rats 14 and 28 days after transplantation	27403
@VP	treated	27612
@VP	treated	27627
@VP	treated	27790
@VP	treated	27805
@VP	treated	28006
@VP	treated	28021
@VP	treated	28278
@VP	treated group	28441
@VP	treated group	28462
@VP	had declined	28508
@VP	declined	28512
@VP	treated group	28639
@VP	treated group	28660
@VP	exerts antiapoptotic effects in adult rats after SCI	28860
@VP	compared with control groups 28 days after transplantation -LRB- > 0.05 -RRB-	29943
@VP	had little change in each group -LRB- Figure 6 -LRB- b -RRB- -RRB-	30184
@VP	can be correlated with the functional recovery of rats	30432
@VP	be correlated with the functional recovery of rats	30436
@VP	correlated with the functional recovery of rats	30439
@VP	treated	30561
@VP	treated	30575
@VP	treated groups and control groups	30594
@VP	treated group	30924
@VP	treated group	30945
@VP	4	31374
@VP	being experimentally	31447
@VP	promising for therapy of SCI -LSB- 27 -- 30 -RSB-	31468
@VP	To take advantage but obviate the limitations ofOECs and BMSCs	31661
@VP	take advantage but obviate the limitations ofOECs and BMSCs	31664
@VP	take advantage	31664
@VP	obviate the limitations	31683
@VP	has been suggested as therapeutic for SCI	31779
@VP	been suggested as therapeutic for SCI	31783
@VP	suggested as therapeutic for SCI	31788
@VP	verified the cells immunofluorescence	31941
@VP	measured the viability of the individual	31983
@VP	cocultured cells	32028
@VP	to avoid the imbalance in the proportion of cells in the coculture system	32295
@VP	avoid the imbalance in the proportion of cells in the coculture system	32298
@VP	is able to promote functional recovery of rats after SCI	32504
@VP	to promote functional recovery of rats after SCI	32512
@VP	promote functional recovery of rats after SCI	32515
@VP	suggested that the two cell typesmay interact in a synergistic way	32710
@VP	interact in a synergistic way	32747
@VP	to improve the functional recovery of SCI	32777
@VP	improve the functional recovery of SCI	32780
@VP	is consistent with our findings	33085
@VP	had themost effective change compared with that of OECs and BMSCs alone	33166
@VP	themost effective change compared with that of OECs and BMSCs alone	33170
@VP	appears to be susceptible for therapeutic intervention	33481
@VP	to be susceptible for therapeutic intervention	33489
@VP	be susceptible for therapeutic intervention	33492
@VP	using TUNEL assay which showed	33966
@VP	showed	33990
@VP	treated	34046
@VP	treated	34061
@VP	was significantly lower compared with that in the sham groups	34102
@VP	treated	34276
@VP	treated groups 28 days after transplantation	34294
@VP	thus contributing probably to the apoptotic death of cells in the spinal cord	34530
@VP	treated group compared with those in the sham groups	35167
@VP	had little change in each group	35252
@VP	may be directly associated with the release of Caspase-9 and Caspase-3	35386
@VP	be directly associated with the release of Caspase-9 and Caspase-3	35390
@VP	directly associated with the release of Caspase-9 and Caspase-3	35393
@VP	resulted in apoptosis after SCI	35486
@VP	leading to a decrease in the number of apoptotic cells	35786
@VP	treated group	35861
@VP	recover functional activities of rats after two weeks of transplantation	36252
@VP	treated group and BMSCs treated group 21 and 28 days after transplantation	36553
@VP	treated group 21 and 28 days after transplantation	36577
@VP	provides a potential therapeutic target in the treatment of SCI	36742
@VP	migrate and accumulate in the injured areas	36897
@VP	differentiate into neural cells	36942
@VP	improve the functional recovery of these animals	36979
